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ABSTRACT 
Induced pluripotent stem cells (iPS cells) resemble embryonic stem cells (ES cells) and 
can differentiate into all cells of our body. Thereby, iPS cells provide unique opportunities 
for disease modeling, drug development and regenerative medicine. Autologous iPS 
cells and their differentiated progenies are thought to bypass immune rejection and are 
therefore particularly appealing for personalized medicine. However, this assumption has 
remained controversial: syngeneic mouse iPS cells were found to be immunogenic and 
got rejected upon transplantation, while in other studies syngeneic iPS cells and their 
derivatives showed either “negligible” or “lack of” immunogenicity upon transplantation. 
All studies used fibroblasts as starting cells for iPS cell generation, which might influence 
iPS cell immunogenicity due to somatic memory effects. 
 
Testicular Sertoli cells provide an immune-privileged environment for developing germ 
cells in testis and exhibit an immune-privileged function. Here, C57BL/6 (B6) Sertoli cells 
were used to generate iPS cells and then injected into syngeneic mice to test for their in 
vivo immunogenicity in teratoma assay. Teratoma assay allows assessing in vivo 
immunogenicity of iPS cells and their differentiated progeny simultaneously. We found 
that early-passage Sertoli iPS cells (Ser-iPS) showed reduced immunogenicity 
compared to iPS cells from B6 mouse embryonic fibroblast (MEF-iPS). Ser-iPS formed 
significantly more teratomas and showed less immune cell infiltration and tissue damage 
and necrosis than MEF-iPS. Embyoid bodies (EBs) of Ser-iPS cells exhibited reduced T 
cell activation potential compare to MEF-iPS cells and showed a reduced 
immunogenicity similar to syngeneic ES cells. However, teratoma formation frequency 
for late-passage Ser-iPS cells was similar to MEF-iPS cells. These findings indicate that 
early-passage iPS cells retain some somatic memory that impacts on iPS cell properties. 
These data suggest that immune-privileged Sertoli cells might represent a preferred 
target for iPS cell generation, if it comes to use of iPS cell derivatives for transplantation. 
 
Transdifferentiation represents yet another promising method of reprogramming one cell 
type into another. Successful transdifferentiation of fibroblasts into several cell types has 
been achieved, such as neurons, cardiomyocytes, hepatocytes and blood cells. Here, I 
attempted to transdifferentiate MEF from Vav-iCre/ROSA26R-fGFP reporter mice (Vav-
MEF) into Vav-GFP+ hematopoietic cells by Oct4 and Oct4 plus Bmi1. Infection of CD45 
MACS depleted Vav-MEF by Oct4 and Oct4 plus Bmi1 yielded Vav-GFP+ hematopoietic 
cells. However, hematopoietic cells failed to show up after transfection of CD45 plus 
Vav-GFP FACS depleted Vav-MEF with the same methods. These findings indicate that 
Oct4 or Oct4 plus Bmi1 do not have the potential to transdifferentiate MEF into blood 
cells. Screening for further transcriptional factors, which are important for hematopoiesis, 
will be necessary for successful transdifferentiation into hematopoietic cells. 
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ZUSAMMENFASSUNG 
Induzierte pluripotente Stammzellen (iPS Zellen) können ähnlich wie embryonale 
Stammzellen (ES Zellen) in alle Körperzellen des menschlichen Organismus 
differenzieren und bieten daher einzigartige Möglichkeiten bei der Erforschung von 
Krankheiten, der Medikamentenentwicklung und in der regenerativen Medizin. So 
könnten bei Verwendung von autologen iPS Zellen und daraus differenzierter Zellen 
Abstoßungsreaktionen vermieden werden und diese Zellen sind daher besonders 
interessant für die personalisierte Medizin. Allerdings wird diese Annahme bisher 
kontrovers diskutiert. In einigen Studien wurden isogene iPS Zellen von Mäusen nach 
der Transplantation abgestoßen. Andere Studien berichteten von keiner oder einer 
vernachlässigbaren Immunogenität solcher iPS Zellen und der aus ihnen differenzierten 
Zellen. Alle bisherigen Untersuchungen nutzten iPS Zellen, die aus Fibroblasten 
generiert wurden. Da iPS Zellen ein somatisches Gedächtnis besitzen, ist es möglich, 
dass die Immunogenität von iPS Zellen von den ursprünglich zur Reprogrammierung 
verwendeten Zellen abhängt. 
 
Sertoli Zellen aus dem Hoden besitzen die Fähigkeit, eine vor dem Immunsystem 
geschützte Umgebung zu schaffen, was für die Entwicklung von Keimzellen im Hoden 
wichtig ist. In der vorliegenden Arbeit wurden iPS Zellen aus C57BL/6 (B6) Sertoli Zellen 
generiert und in isogene Mäuse injiziert, um deren Immunogenität in Teratomen zu 
untersuchen. Der Teratom Assay erlaubt die gleichzeitige Bewertung von Immunogenität 
und Differenzierungspotential von iPS Zellen in vivo. Es konnte gezeigt werden, dass 
aus Sertoli Zellen abgeleitete iPS Zellen (Ser-iPS) in frühen Passagen eine verringerte 
Immunogenität aufweisen und nach der Injektion in isogene Empfänger signifikant mehr 
Teratome bildeten als von Maus embryonalen Fibroblasten (MEF) abgeleitete iPS Zellen 
(MEF-iPS). Diese Teratome von Ser-iPS wiesen eine geringere Infiltration durch 
Immunzellen und weniger Gewebeschädigungen durch Nekrose auf als Teratome von 
MEF-iPS Zellen. Embryoid bodies (EB) von Ser-iPS zeigten außerdem ein reduziertes 
Potenzial T-Zellen zu aktivieren, im Vergleich zu MEF-iPS, und ihre Immunogenität war 
vergleichbar mit der von isogenen ES Zellen. Im Gegensatz dazu war die Teratomrate 
von Ser-iPS aus späten Passagen vergleichbar mit der von MEF-iPS. Zusammengefasst 
zeigen die Daten, dass das somatische Gedächtnis von iPS Zellen deren Eigenschaften 
beeinflusst. Daher sind immun-priviligierte Sertoli Zellen zur Generierung von iPS Zellen 
zu Transplantationszwecken ein bevorzugter Zelltyp. 
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Transdifferenzierung ist eine in vitro Differenzierungsmethode, die einen Zelltyp direkt in 
einen anderen umwandelt, ohne den Schritt der Reprogrammierung zur pluripotenten 
Stammzelle. Diese Art der Differenzierung wird vielfach angewendet, und es konnten 
erfolgreich z. B. Neurone, Herzmuskelzellen, Leberzellen und Blutzellen generiert 
werden. In dieser Studie sollten MEF von Vav-iCre/ROSA26R-fGFP Reporter-Mäusen 
(Vav-MEF) durch die Einführung von Oct4 oder Oct4 plus Bmi1 in hämatopoetische Vav-
GFP+ Zellen transdifferenziert werden. Dazu wurden MEF mittels (i) MACS oder (ii) 
FACS von CD45+-Zellen depletiert und mit den Transkriptionsfaktoren Oct4 bzw. Oct4 
plus Bmi1 infiziert. Es wurde gefunden, dass nach stringenter FACS Depletion der MEF 
mit Oct4 oder Oct4 plus Bmi1 keine hämatopoetischen Zellen erhalten werden konnten. 
Diese Ergebnisse weisen darauf hin, dass Oct4 und Bmi1 nicht ausreichen, um MEF zu 
hämatopoetischen Zellen zu transdifferenzieren. Nachfolgende Studien sind nötig, um 
weitere Transkriptionsfaktoren für eine erfolgreiche Transdifferenzierung zu finden. 
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1 INTRODUCTION 
1.1 Somatic cell reprogramming 
Embryonic stem cells (ES cells), which exist transiently in the inner cell mass of 
mammalian blastocysts, represent one of the best-understood pluripotent stem cell types. 
Mouse ES cell lines were firstly established in 1981 from mouse pre-implantation 
embryos. Mouse ES cells have the ability to expand and grow without limitation while 
maintaining their pluripotentcy, and the ability to differentiate into cell derivatives of all 
three germ layers (Evans and Kaufman 1981; Martin 1981). The establishment of mouse 
ES cell lines stimulated the discovery of human ES cells, which were first generated by 
Thomson and colleagues from in vitro fertilization produced blastocysts (Thomson et al., 
1998). Human ES cells possess similar characteristics to mouse ES cells, such as 
indefinite self-renewal and pluripotent differentiation potential (Smith 2001) and cell 
derived thereof might be useful for treatment of diseases (Thomson et al., 1998). 
However, ethical issues challenge the use of human embryos. One way to circumvent 
these issues is to generate pluripotent cells in vitro. The increasing understanding of 
pluripotency of ES cells allowed generation of pluripotent cells from somatic cells, which 
is referred to as reprogramming. Several methods can be used for reprogramming 
somatic cells into a pluripotent state, such as somatic cell nuclear transfer (SCNT; 
Wilmut et al., 1997) and cell fusion (Tada et al., 2001). However, due to their rather low 
efficiency and potential risks, these methods are not widely used. 
1.1.1 Induced pluripotent stem (iPS) cells 
Generation of iPS cells 
Cells derived form patient-specific pluripotent stem cells have the potential to be applied 
for clinical treatment of diseases. Both SCNT and cell fusion can generate pluripotent 
cells, but they have disadvantages, which prevented their use in the clinics. Until 2006, a 
landmark study by Yamanaka group demonstrated that mouse embryonic or adult 
fibroblasts can be reprogrammed into iPS cells by ectopic expression of four 
transcriptional factors octamer-binding protein 4 (Oct4), sex determining region Y-box 2 
(Sox2), krüppel-like factor 4 (Klf4) and v-myc myelocytomatosis viral oncogene homolog 
(c-Myc; OSKM; Takahashi and Yamanaka 2006). iPS cells exhibited similar properties to 
ES cells, including pluripotency, differentiation capacity and the potential to produce 
viable mice by tetraploid complementation (Zhao et al., 2009). iPS cells have been 
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generated from a broad rang of cell types, including terminally differentiated cells, and 
cells come from all three germ layers (ectoderm, mesoderm and endoderm). Additionally, 
iPS cells can be generated with different combination of transcriptional factors (Hanna et 
al., 2008; Kim et al., 2009; Liu et al., 2010). iPS cells were also generated from various 
species, such as human, monkey, rat and pig (Liao et al., 2009; Liu et al., 2008; 
Takahashi et al., 2007; Wu et al., 2009; ). Surprisingly, iPS cells were also generated in 
vivo, which exhibited both embryonic and extraembryonic differentiation potential (Abad 
et al., 2013). This new method for iPS cell generation represents a powerful strategy for 
regenerative medicine and tissue reprogramming in situ. 
 
Generation of iPS cells can be achieved by integration and integration-free methods. 
Based on the vector types being used, the induction methods are divided into four 
categories: virus, DNA (plasmid), protein or RNA (Mochiduki and Okita 2012). iPS cells 
were initially generated by ectopic expression of reprogramming factors with retroviral or 
lentiviral vectors (Takahashi and Yamanaka 2006; Yu et al., 2007). However, potential 
tumorigenic effects due to insertional mutagenic lesions of retrovirus or lentivirus 
question the application of iPS cells containing integrated vector DNA, although the Cre-
LoxP system can be used to remove transgenes (Soldner et al., 2009). To generate iPS 
cells with minimal or absence of genetic modification, various non-integration methods 
have also been developed (Okita et al., 2008; Yu et al., 2009).  
 
Plasmid vectors were reported to induce mouse iPS cell generation, but with low 
efficiency (less than 0.0002%, Okita et al., 2008). Then, an episomal plasmid system 
was employed to generate human iPS cells (Yu et al., 2009). However, with these DNA-
based vector methods, genomic integration can also occur at a low frequency. To 
entirely avoid potential integration of vector DNA into chromosomal DNA, one possible 
strategy is protein transduction. Zhou and colleagues use several cycles of purified poly-
arginine tagged OSKM proteins to successfully generate iPS cells from mouse 
embryonic fibroblast (MEF) (Zhou et al., 2009). By using a similar method, iPS cells were 
obtained from human newborn fibroblasts after several rounds of supplement with 293 
cell extracts expressing poly-arginine tagged OSKM genes (Ko et al., 2009). Another 
promising method to generate iPS cells without genetic modification is microRNA 
transduction (Telpalo-Carpio et al., 2013). Human iPS cells were generated at high 
efficiency by the application of modified mRNA containing OSKM transcriptional factors 
or by miRNA (Anokye-Danso et al., 2011; Warren et al., 2010). It is also possible to 
generate iPS cells by highly reproducible RNA-based approach, such as using a single, 
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synthetic self-replicating VEE-RF RNA replicon that expresses OSKM reprogramming 
factors (Yoshioka et al., 2013). Additionally, human iPS cells were efficiently generated 
by application of Sendai virus-based vector system (Fusaki et al., 2009). Sendai virus is 
a negative sense, single-stranded RNA virus and belongs to Paramyxovirdae family 
(Lamb and Kolakofsky 1996). Furthermore, recombinant Sendai virus vectors do not go 
through a DNA stage nor integrate into the genome of the host cells (Li et al., 2000). 
Thus, Sendai virus-based vector system prodives a critical method for cell 
reprogramming without DNA integration. Although diverse strategies for iPS generation 
have been rapidly developed, more efficient and safe methods are still necessary for 
generating clinically useful iPS cells.  
 
With the development of iPS technology, more and more details involved in the 
reprogramming process have been clarified. Based on gene expression during OSKM-
induced MEF reprogramming, the multistep processes of iPS generation were 
characterized by three phases: initiation, maturation and stabilization (Samavarchi-
Tehrani et al., 2010). The initiation phase marks a process referred to as mesenchymal 
to epithelial transition (MET), which suppressed the pro-epithelial to mesenchymal 
transition signals (Li et al., 2010). The stabilization phase depends on the removal of 
transgene expression, which is required for the maturation phase (Golipour et al., 2012). 
Transcription factor induced reprogramming is generally an inefficient and stochastic 
event due to the “rate-limiting step”, which is an unknown step in the transition from 
somatic cells to iPS cells (Buganim et al., 2013). Recently, Tanabe and colleagues 
showed that maturation, not initiation, limits direct reprogramming of human fibroblasts to 
pluripotency state (Tanabe et al., 2013). However, the rate-limiting step can be 
overcomed by depleting methyl-CpG binding domain protein 3 (Mbd3; a core member of 
the Mbd3/NuRD repressor complex) together with OSKM transduction. With this method, 
mouse and human somatic cells can be reprogrammed into iPS cells with 100% 
efficiency (Rais et al., 2013). 
 
Although much progress has been made in understanding the complex reprogramming 
process, many questions related to the molecular mechanism during reprogramming 
remain unsolved. Addressing these unsolved problems will be required for deeper 
understanding of the reprogramming process and further application of iPS cells in 
clinical therapy. 
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Figure 1.1. The battle of pluripotency. 
Elimination of Mbd3 enabled efficient activation of dormant stem-cell genes, allowing almost all 
starting cells to be converted into pluripotent state (Loh and Lim 2013). 
 
Differentiation of iPS cells 
Three-germ layer differentiation potential of iPS cells is another important property of iPS 
cells further to their unlimited self-renewal potential. Frequently, differentiation potential 
of iPS cells is examined in embryoid body (EB) assay in vitro and teratoma assay in 
immune deficient mice in vivo. iPS cells differentiate into a variety of cell types, such as 
lung and airway progenitors, cardiomyocytes and hepatic progenitor cells (Mou et al., 
2012; Kawamura et al., 2012; Yanagida et al., 2013). For in vitro analysis or in vivo 
transplantation, specifical differentiated cell type in large quantities from iPS cells is a 
precondition. However, the development of methods favoring the efficient differentiation 
of iPS cells into one specfic cell type has been challenged. Knockdown of Sox2 can 
accelerate differentiation of pluripotent stem cells (De et al., 2014). Small molecules, 
such as ascorbic acid, are attractive agents to direct specific cell differentiation, (Cao et 
al., 2012). Interestingly, iPS cells have been differentiated in vivo into human 
hematopoietic cells in teratoma assays. These hematopoietic cells were transplantable 
and reconstituted the human immune system (Amabile et al., 2013). This study provides 
a new concept to obtain specific differentiated cells from iPS cells.  
 
While there is progress in differentiation protocols for iPS cells, some limitations still 
remain. The potential tumorigenic risk, due to contaminating undifferentiated cells in 
differentiated products, is one of the biggest roadblocks for their clinical application (Tang 
and Drukker 2011). Immunodepletion with antibodies against human iPS cells and with 
two additional pluripotency surface markers have proved feasible to deplete 
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undifferentiated cells (Tang et al., 2011). Additionally, both low differentiation efficiency 
and the immature phenotype of differentiated cells are critical limitations of current 
differentiation protocols (Oshima et al., 2010). The long-standing question is to generate 
mature and functional cells with high efficiency and purity, which is important for 
therapeutic transplantation, in vitro drug screening and disease research. 
 
Epigenetic memory in iPS cells 
iPS cells have been obtained from numerous somatic cell types, including fibroblasts, 
keratinocytes, B-lymphocytes, hepatocytes and stomach cells (Stadtfeld et al., 2008; 
Aasen et al., 2008; Hanna et al., 2008; Aoi et al., 2008). An interesting question is 
whether there are differences among iPS cell lines derived from different cell origins. 
Gene expression profiles of different human iPS cell lines showed that iPS cells retained 
significant donor cell gene expression (Chin et al., 2009; Marchetto et al., 2009; Ghosh 
et al., 2010; Bar-Nur et al., 2011). More interestingly, when iPS cells derived from human 
cells or from the same mouse but different cell types, resulting iPS cells cluster together 
according to their cell of origin by DNA methylation analysis (Polo et al., 2010; Kim et al., 
2010; Lister et al., 2010; Ohi et al., 2011; Kim et al., 2011b ). Furthermore, these iPS 
cells were more likely to re-differentiate into the somatic cell lineage used for 
reprogramming than unrelated lineages (Polo et al., 2010; Kim et al., 2010; Pfaff et al., 
2012). Epigenetic memory that favors iPS cell re-differentiation into the cell type of origin 
has been reported in human iPS cells derived from different somatic cell types (Hu et al., 
2010; Bar-Nur et al., 2011; Kim et al., 2011b). In vivo experiments indicated that, the 
teratoma-forming potential of neurospheres has marked differences depending on the 
tissue origin of iPS cells (Miura et al., 2009). The mechanisms of different teratoma 
formation potential are still elusive, but could be related to the somatic memory in iPS 
cells from distinct tissues that affects the differentiation propensity of resulting iPS cells 
(Bilic and Izpisua Belmonte 2012). 
 
It is important to note that, in some of these studies, early-passage mouse iPS cells (p4-
6) or human iPS cells (p<20) were used for analysis (Polo et al., 2010; Kim et al., 2010; 
Ohi et al., 2011). However, prolonged passaging of iPS cells removed the differences in 
gene expression profiles. These late-passage iPS cells failed to cluster together 
according to their cell of origin (Chin et al., 2009; Chin et al., 2010; Polo et al., 2010). In 
addition, treatment with chemical reagent 5-azacytidine (AZA) or using several 
differentiation-reprogramming periods into the desired direction, erased the 
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differentiation propensity ability of iPS cells (Kim et al., 2010).  
 
It seems that fully reprogramming takes longer, and requires several passages even 
after the emergence of ES cell-like morphology and expression of pluripotency markers 
(Bilic and Izpisua Belmonte 2012). It is still unclear if epigenetic reprogramming 
continues during extended culturing, or if fully reprogrammed cells are selected during 
passaging, or if exogenous reprogramming factors get silenced with time (Papp and 
Plath 2011). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.2. iPS cells have different differentiation capacity. 
iPS cells often have more potential to differentiate towards cell types related to the lineage they 
come from (wide arrows) over towards the unrelated cell types (dotted arrows; Cherry and Daley 
2013). 
 
Although iPS cells continue to offer great prospects for therapeutic applications, 
substantial research and development are still needed before the application of iPS cell-
based cell therapies. On the other hand, differentiation bias of iPS cells may be 
advantageous in generation of specific cell types that currently are difficult to produce in 
vitro for certain research and therapeutic application. 
 
Application of iPS cells 
iPS cells are an attractive source for disease research when a sufficient number of 
primary cells from patient are difficult to obtain. One way that iPS cells will influence 
modern medicine is the generation of iPS cells from individual patient with recognized 
disease characters. Indeed, disease-specific iPS cells are available for a broad range of 
diseases, such as Parkinson disease (Soldner et al., 2009), diabetes type I (Maehr et al., 
2009) and cystic fibrosis (Somers et al., 2010). Disease-based iPS cells are expected to 
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contribute to disease research in two aspects: (i) as the basis for drug screening that 
may be used as therapeutics and (ii) as tools for disease mechanism studies (Cherry 
and Daley 2013). The aim to create disease-specific iPS cell is to identify the disease 
phenotype and correct the defective gene(s) for further use in the patient (Unternaehrer 
and Daley 2011). Despite considerable progress made in disease-specific iPS cells, 
utilization of these cells for understanding disease mechanisms and developing 
therapies is just at the beginning.  
1.1.2 Transdifferentiation 
In the stem cell field, the possibility of direct cell fate conversion has attracted great 
interest for patient-specific cell therapy. Although larger quantity of pluripotent stem cells 
and easy genetic correction can be achieved by iPS technology, the complexity for iPS 
generation and their high risk of tumorigenesis are challenges for their clinical application. 
An alternative method for reprogramming is transdifferentiation, which can convert one 
cell type directly into another, without a detour via pluripotent state. 
 
Whether different cell fates are interchangeable have already been addressed decades 
ago. Lassar and colleagues discovered for the first time that exogenous expression of 
transcription factor myoblast determination induced muscle-specific properties in 
fibroblast (Davis et al., 1987). Subsequently, studies for successful cell fate conversion 
increase at a remarkable speed. Transdifferentiation of mouse B-lymphocytes into 
macrophages, mouse pancreatic acinar cells to beta-islet cells have already been proved 
feasible (Xie et al., 2004; Zhou et al., 2008). All these previous studies induced 
transdifferentiation only between lineages within the same germ layer. However, whether 
cell fate conversion between different germ layers is possible remained to be 
investigated. It was not until 2010 that Wernig and colleagues achieved the conversion 
from mouse fibroblasts (mesoderm) to neurons (ectoderm), showing for the first time that 
cell fate conversion across germ layers is feasible (Vierbuchen et al., 2010). These 
experiments were performed on mouse cells.  
 
Recently, a number of reports have made great progress in directing human fibroblasts 
to neural cells/specific neuronal subtypes (Ambasudhan et al., 2011; Son et al., 2011; 
Pfisterer et al., 2011; Caiazzo et al., 2011). Furthermore, fibroblasts and Sertoli cells can 
also be transdifferentiated into neural stem/progenitor cells by the combination of 
different transcriptional factors or even by sox2 alone (Sheng et al., 2011; Kim et al., 
2011a; Lujan et al., 2011; Han et al., 2012; Thier et al., 2012; Ring et al., 2012). 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
INTRODUCTION 
                                                                                                                                 	  
	  	   8	  
Transdifferentiation into neurons was even achieved in vivo (Torper et al., 2013; Rouaux 
and Arlotta 2013; Niu et al., 2013). Additionally, transdifferentiation into other cell types is 
also possible, such as transdifferentiation into cardiomyocyte/cardiac progenitors, 
hepatocytes, embryonic Sertoli-liked cells and multilineage blood progenitors/hemogenic 
cells (Ieda et al., 2010; Szabo et al., 2010; Sekiya and Suzuki 2011; Huang et al., 2011; 
Efe et al., 2011; Islas et al., 2012; Buganim et al., 2012; Pereira et al., 2013). More 
importantly, transdifferentiation of human mesenchymal stem cells (MSC) and fibroblasts 
to hematopoietic cells was achieved by treating with chemical reagent AZA and growth 
factors (Harris et al., 2011). Moreover, hepatocytes derived from human fibroblasts were 
reported to reconstruct mouse livers (Zhu et al., 2014). Transdifferentiation was also 
possible in other species, such as porcine and rat (Zhu et al., 2012; Yang et al., 2013). 
Like iPS cell technology, transdifferentiation can be used for examining disease 
mechanisms. Induced neural cells from patient’s fibroblasts reproduced the disease 
phenotypes observed in endogenous neurons, thus validating the use of induced neural 
cells for disease research (Qiang et al., 2011; Chanda et al., 2013).  
 
Transdifferentiation can be used to turn one cell type directly to another cell type in a 
shorter time in a relative simple procedure. Transdifferentiation represents a valuable 
method for cell replacement therapy. However, generation of specialized cell type with 
sufficient quantity remains a great challenge. Considering the common concerns for cell 
reprogramming, the existence of somatic memory in transdifferentiated cells is possible. 
Overall, considerable work is still required to find a most appropriate method for 
production of specific cell types with therapeutic application. 
1.2 Hematopoietic cells 
Hematopoietic stem cells (HSC) derived from blood and bone marrow (BM) are 
responsible for constant self-renewal and differentiate to a variety of specialized blood 
cells. Currently, no other stem cells have been best-characterized like HSC and actually 
used in therapy. The existence of HSC is first discoved by Till and McCulloch in 1961 
(Till and Mc 1961). Since then, studies about phenotype and functional characteristics of 
HSC have rapidly developed. However, challenges for HSC assay and application are 
how to identify HSC and keep them proliferating in vitro. 
1.2.1 Generation of hematopoietic cells in vitro 
Generation of hematopoietic cells from pluripotent stem cells 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
INTRODUCTION 
                                                                                                                                 	  
	  	   9	  
To discover how hematopoietic cells emerge during embryonic development is a good 
start for better understanding of hematopoietic cells’ properties. Embryos can 
differentiate into cells of all three germ layers, including hematopoietic cells. In 1985, it 
was shown for first time that hematopoietic precursors can be obtained during EB 
differentiation of mouse ES cells (Doetschman et al., 1985). Generation of hematopoietic 
cells from human ES cells has also been reported, as evidenced by the production of 
gamma-globin, a blood protein (Itskovitz-Eldor et al., 2000). In vitro differentiation of ES 
cells recapitulate early hematopoietic development and follow-up studies about 
hematopoietic cell generation have been described. 
 
After development of iPS technology it is feasible to generate hematopoietic cells from 
iPS cells. iPS technology has been applied to cure hematopoietic diseases (sickle cell 
anemia) in humanized mouse model (Hanna et al., 2007). Although pluripotent stem 
cells have advantages in clinical application, problems remain. For example, human 
hematopoietic cells derived from pluripotent stem cells in vitro failed to reconstitute the 
entire hematopoietic system (Wang et al., 2005;Doulatov et al., 2013). However, a recent 
study showed that human hematopoietic stem/progenitor cells could be generated in vivo 
by teratoma assay in immunocompromised mice. Furthermore, these hematopoietic 
stem/progenitor cells could reconstitute human immune system in immunodeficient mice 
(Amabile et al., 2013). This method is particularly appealing for those cell types that are 
normally difficult to obtain from pluripotent stem cells in vitro. Yet, the method bears the 
problem of possible tumorigenesis and requirement of sufficient quantities for clinical 
application. 
 
Generation of hematopoietic cells from somatic cells 
With the development of transdifferentiation technology, numerous successful 
transdifferentiation experiments have been reported. Moreover, successful 
transdifferentiation into multilineage blood progenitors has been achieved by ectopic 
expression of Oct4 together with hematopoietic cytokines in human fibroblasts (Szabo et 
al., 2010). Such hematopoietic cells gave rise to granulocytic, monocytic, 
megakaryocytic and erythroid lineages, and possessed engraftment capacity in vivo. 
More recently, mouse fibroblasts transfected with other transcriptional factors (Gata2, 
Gfi1b, cFos and Etv6) can be efficiently induced to hematopoietic progenitors (Pereira et 
al., 2013). Furthermore, human MSC and skin fibroblasts can be transformed to 
hematopoietic cells by treating exclusively with demethylating reagent AZA and growth 
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factors (Harris et al., 2011). These findings indicate an alternative approach to obtain 
hematopoietic cells, which are normally difficult to get from pluripotent stem cells in vitro 
for autologous cell replacement therapies. 
1.2.2 Gene regulation during hematopoiesis 
Self-renewal and differentiation of HSC have been tightly controlled by a number of 
transcriptional factors (McKinney-Freeman et al., 2012). Several transcription factors 
play important roles during hematopoiesis. Polycomb group proteins, which control 
embryonic development by inhibiting homeotic gene expression, were initially discovered 
in Drosphila (Muyrers-Chen et al., 2004). Polycomb repressive complex 1, one of the 
polycomb group protein complexes, has been well described. B lymphoma Mo-MLV 
insertion region 1 homolog (Bmi1), a key component of polycomb repressive complex 1, 
is selectively expressed in various kinds of adult stem cells, such as HSC and neural 
stem cells (Park et al., 2003; Molofsky et al., 2005). The role of Bmi1 in the maintaining 
adult stem cell pool is mainly by repression of Ink4a/Arf locus, which encodes inhibitors 
of cell cycle kinase p16Ink4a and p19Arf (Akala et al., 2008). 
 
Function of Bmi1 in HSC was also investigated in Bmi1 deficient (Bmi1-/-) mice and 
competitive transplantation experiments (Lessard and Sauvageau 2003; Park et al., 
2003). Accordingly, overexpression of Bmi1 increases self-renewal of HSC in both the 
mouse and the human system (Iwama et al., 2004; Rizo et al., 2008). Furthermore, 
potential of Bmi1 in promoting hematopoietic cell development from ES cells has been 
reported (Ding et al., 2012). Increasing evidence of Bmi1 function in maintaining self-
renewal of adult stem cells and enhancing hematopoietic cell development from ES cells 
indicates that Bmi1 plays a major role during hematopoiesis. However, whether Bmi1 is 
crucial for transdifferentiation somatic cells into hematopoietic cells has so far not been 
studied. 
1.3 Sertoli cells 
Sertoli cells are first discovered by Sertoli in 1865. Sertoli cells, together with different 
stages of sperm cells and peritubular myoid cells, form the seminiferous tubules of testis. 
They extend from the basement membrane, which is formed by myoid cells, to the lumen 
of seminiferous tubules, completely surrounding the developing germ cells. Sertoli cells 
provide nutrients and immune-protective factors to support the development of germ 
cells (Griswold 1998) and Sertoli cells are crucial for spermotogenesis and adult fertility. 
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1.3.1 Sertoli cell development 
During mouse development the gonads were morphologically indistinguishable until at 
about 12.5 days post coitum (dpc), when testis cords formed in male about 48 hours 
after sex determining region of Y chromosome (Sry) expression (Gubbay et al., 1990). 
Sertoli cells, the primary structural composition of testicular seminiferous tubules, 
epithelialize and enclose germ cells and are surrounded by peritubular myoid cells to 
form a tubular structure. Sertoli cells play a key role in sex determination. They were 
regarded to be the first somatic cell type to differentiate in the testis (Karl and Capel 
1998). Moreover, they were the only cell type in testis required to possess a Y 
chromosome and direct other testicular somatic cells to male pathway (Burgoyne 1988).  
 
To better understand how Sertoli cells direct testis development, it is essential to know 
from where they emerge. Previously, Sertoli cells have been proposed to derive from 
coelomic epithelium, mesonephros, or both (Byskov 1986). Subsequent studies indicated 
that cell types from mesonephros that migrated into male gonad were peritubular myoid 
cells and endothelial cells (Merchant-Larios et al., 1993), while Sertoli cells derived from 
coelomic epithelial between tail somite 15 and 17 stages (Karl and Capel 1998). 
 
Many cell types are considered as terminally differentiated cells, including Sertoli cells 
(Chaudhary et al., 2005). Sertoli cells proliferate more rapidly before birth and keep on 
proliferating for another 2 weeks (mice) to 3 weeks (rats) after birth (Orth 1982; 
Vergouwen et al., 1991). During puberty, Sertoli cells progressively cease proliferation, 
fix their morphology and physiology and become terminally differentiated cells (Jegou 
1992). Thereafter, nucleus of Sertoli cells enlarges and nucleolus becomes more 
prominent. Furthermore, tight junctions form between adjacent Sertoli cell membranes, 
which are termed blood-testis barrier (BTB), to create unique adluminal compartments 
(Sharpe et al., 2003). However, recently it has been shown that Sertoli cells from adult 
mouse and human have the potential to proliferate during in vitro culture (Ahmed et al., 
2009). In addition, adult Sertoli cells from hamsters regained their proliferative capacity in 
vivo (Tarulli et al., 2006). 
1.3.2 Sertoli cell function  
Immune-privileged sites are places where autoantigens or foreign antigens are tolerated 
for extended periods of time without raising detrimental immune responses (Barker and 
Billingham 1977). Testis is an immunologically privileged site that not only protects auto-
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immmuogenic male germ cells but also provides tolerogenic environment for the survival 
of foreign tissues without any immunosuppressive drugs (Barker and Billingham 1977). 
Sertoli cells have been identified as key players for creating immune-privileged testicular 
environment (Whitmore et al., 1985). A number of mechanisms contribute to this 
immune-privileged function of Sertoli cells. 
 
Blood-testis barrier 
The BTB, formed between adjacent Sertoli cell membranes, provides the physical 
immune protective role for germ cells. BTB prevents auto-immunogenic germ cells from 
rejecting by systematic circulation (Cheng and Mruk 2002). However, BTB is only 
partially responsible for the immune-privileged function of Sertoli cells. Because 
spermatogonia cells, which locate outside BTB and are immunogenic, yet are not 
attacked by immune system (Yule et al., 1988). This suggests that, not only BTB, but 
also factors secreted by Sertoli cells are important for establishment and maintenance of 
the testicular immune-privileged environment. 
 
Induction of peripheral tolerance 
Immune-modulatory factors secreted by Sertoli cells facilitate the formation of testical 
immune-privileged environment and avoid immune rejection. Immune responses involve 
immune cells, such as T cell, B cell and macrophage. In vitro experiments showed that 
Sertoli cells inhibit the proliferation of B cells and T cells (Wyatt et al., 1988; Selawry et 
al., 1991; De Cesaris et al., 1992). Inhibition of T cell proliferation by Sertoli cells was 
through arresting T cells in G1 phase of the cell cycle (Wyatt et al., 1988; Selawry et al., 
1991; De Cesaris et al., 1992). This related to the decreased production of interleukin-2 
(IL-2) and could not be compensated by addition of exogenous IL-2 (Selawry et al., 1991; 
De Cesaris et al., 1992).  
 
Evidences from islet cell allogeneic transplantation into mouse testis indicated that T 
cells underwent apoptosis after entering into testicular environment and graft antigen-
specific regulatory T cells (Tregs) increased (Dai et al., 2005; Nasr et al., 2005). 
Consistently, Sertoli cells exhibited the capacity to accelerate Treg generation 
(CD4+CD25+Foxp3+; Dal Secco et al., 2008). These studies indicated that T cells in 
testicular environment could be switched from a type 1 response, which is related to cell-
mediated immunity and rejection, to a type 2 response that is mainly associated with 
immune modulation and tolerogenic (Meinhardt and Hedger 2011). This was confirmed 
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by co-transplanting Sertoli cells and islets into non-obese diabetic mice (Suarez-Pinzon 
et al., 2000). In addition, most of the testicular macrophages showed decreased 
production of proinflammatory cytokines and increased immune-regulatory functions, 
which are the characteristics of type 2 phenotype (Hedger 2002; Maresz et al., 2008). 
Functions of other testicular immune cells, such as natural killer (NK) cell, dendritic cell 
(DC), remain largely unexplored.   
 
Inhibition of complement activation and membrane-associated cell lysis 
The complement system is an enzyme cascade that “complements” the ability of 
antibodies and phagocytic cells to clear pathogens from an organism. Activation of the 
complement cascade leads to hyperacute, acute and chronic graft rejection. The 
immune-privileged function of Sertoli cells was shown to involve resistance of 
complement activation (Doyle et al., 2012). Classical pathway-mediated activation of the 
complement system results in cell lysis by formation of membrane attach complexes 
(Mital et al., 2010). Sertoli cells exhibit resistance to such killing mechanism as 
evidenced by their survival after xenogeneic transplantation and human 
antibody/complement-mediated killing assay (Gores et al., 2003; Dufour et al., 2005). 
Moreover, factors associated with the resistance of complement activation are highly 
expressed in Sertoli cells, such as serine protease inhibitor G1 (SERPING1) and decay-
accelerating factor (DAF/CD55; Murray-Rust et al., 2009; Esposito et al., 2010). 
Additionally, clusterin expressed in Sertoli cells is reported to block membrane attach 
complex-mediated cell lysis (Jenne and Tschopp 1989). These findings indicate that 
resistance of the complement mechanism is important for the immune-privileged function 
of Sertoli cells. 
 
Inhibition of apoptosis through the granzyme-mediated or Fas-Fas ligand (FasL) 
pathways also contributes to the immune-privileged function of Sertoli cells. CD8 T cell 
and NK cell mediated cell killing was via Fas-FasL or granule-mediated pathways 
(Chavez-Galan et al., 2009). Several studies indicated that Sertoli cells express 
SERPINA3N and protease inhibitor-9 (SERPINB9, PI9), which are granzyme B inhibitors 
(Sipione et al., 2006; Bladergroen et al., 2001; Hirst et al., 2001). Furthermore, PI9 has 
been shown to inhibit Fas-FasL induced apoptosis (Cunningham et al., 2007). FasL, a 
member of the tumor necrosis factor family, initiates caspase activation and apoptotic 
cell death by binding to Fas receptor. FasL-expressing Sertoli cells are hypothesized to 
interact with Fas-bearing lymphocytes and result in the death of lymphocytes through 
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apoptosis pathway (Mital et al., 2010). It is found that Fas and FasL also exist in soluble 
forms, sFas and sFasL, which makes their function in testis even more complicated.  
 
Expression of multiple immune-regulating factors 
Sertoli cells secrete multiple cytokines, which play important roles in their immune-
privileged function. Most notable cytokines are members of the transforming growth 
factor β (TGFβ) family. It has already been reported that TGFβ1 supported islet beta-cell 
survival during co-transplantation (Suarez-Pinzon et al., 2000), while TGFβ3 regulated 
the disruption of tight junction, which involves in the protective function of BTB (Lui et al., 
2003). Thus, functions of the TGFβ family in maintaining testicular immune-privileged 
milieu seem to be complex. Inhibiting the expression of indoleamine 2,3 dioxygenase 
(IDO), a tryptophan-metabolising enzyme, abrogates the capability of porcine Sertoli 
cells to protect islet allograft in mice model (Fallarino et al., 2009). Interleukin 6 and 
leukemia inhibitory factor (LIF) secreted by Sertoli cells, provide an immune-privileged 
function by inducing Treg generation and directing type 1 to type 2 immune response 
(Diehl and Rincon 2002; Zenclussen et al., 2006; Doyle et al., 2012). Other molecules 
involved in immune-privileged function of Sertoli cells should be further investigated. It is 
most likely that the interaction of multiple immune-protective factors contributes to the 
immune-privileged function of Sertoli cells. 
 
 
 
 
 
 
 
 
 
 
Figure 1.3. Schematic representation of Sertoli cell immune function. 
Sertoli cells form tubule structures with tight junctions (thick red lines) and increase adhesion to 
lymphocytes, thereby limiting leukocyte migration.  
A: Factors (e.g., cytokines and prostanoids) secreted by Sertoli cells convert the cell-mediated 
immune response to a type 2 response and suppress inflammation, therefore resulting in immune 
tolerance and immune privilege. Green line, adhesion molecules. 
B: Humorally, Sertoli cells express complement inhibitors that inhibit activation of the complement 
cascade and cell lysis, decrease leukocyte recruitment and inflammation, and thus contribute to 
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immune privilege. Green and brown dots, anti-inflammatory molecules secreted by Tregs and 
immature DC; Y, immunoglobulin (Doyle et al., 2012). 
 
Taken together, Sertoli cells provide immune-privileged testicular environment by 
attenuating immune response: increased interactions between cells to decrease 
leukocyte migration; inhibition of complement reaction and inducing a type 2 immune 
response, all of which support an anti-inflammatory response (Doyle et al., 2012).  
1.3.3 Sertoli cell application  
The unique immune protective function of Sertoli cells has been used in co-
transplantation studies, to protect other grafts from immune rejection. Evidence from the 
co-transplantation of Sertoli cells with pancreatic islets showed that Sertoli cells 
significantly prolonged the survival of pancreatic islets (Dufour et al., 2003). Furthermore, 
Sertoli cells have been shown to improve survival of other grafts, such as xenogeneic 
neurons (Willing et al., 1999), xenogeneic liver cells (Rahman et al., 2005), allogeneic 
heart grafts (Lim et al., 2009). In addition, co-tranplantation of porcine Sertoli cells and 
islets into patients with type I diabetes was also feasible (Valdes-Gonzalez et al., 2005; 
Valdes-Gonzalez et al., 2007).  
 
During co-transplantation, Sertoli cells themselves also survive for long periods while 
their protective function for the grafts is lost with time. The long-term survival of Sertoli 
cells indicates that they are useful vehicles for cell-based therapeutic product delivery. 
This idea was first tested by transplanting Sertoli cells expressing green fluorescent 
protein (GFP) reporter gene into kidney capsule and such cells survived for at least 60 
days (Dufour et al., 2004). Afterwards, transplantation of genetically engineered 
therapeutic Sertoli cells carrying human trophic factor, neurotrophin-3 has been studied. 
However, neurotrophin-3 production was only for 3 days (Trivedi et al., 2006). More 
recently, engineered insulin-expressing Sertoli cells have been transplanted into diabetic 
mice. Yet, the decrease of glucose level was transient and mice returned to the diabetic 
state within 8 days (Halley et al., 2010). Although Sertoli cells can be used as potential 
tools for delivery of therapeutic proteins, further studies are needed to improve the 
potential of engineered Sertoli cells. 
1.4 Immunogenicity of pluripotent stem cells  
Pluripotent stem cells can differentiate into all cells of our body and therefore have great 
potential for regenerative medicine (Robinton and Daley 2012). Intensive investigations 
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focus on using functional cells derived from pluripotent stem cells for treating 
degenerative diseases. However, potential immune responses induced by these cells 
are often neglected. At present, immunological restrictions during transplantation have 
not been well addressed and remain a major obstacle for cell replacement therapy. 
1.4.1 Immunogenicity of embryonic stem cells 
Major histocompatibility complex and costimulatory molecules expression 
Major histocompatibility complex (MHC) has been identified as one of the major issues 
during transplantation. Incompatibility of MHC between organ donors and recipients 
results in graft rejection (Bradley et al., 2002). It was originally thought that ES cells 
possessed immune privilege characteristics partially due to their low to undectable 
expression of MHC class I and complete absence of MHC class II antigens and 
costimulatory molecules (CD80 and CD86; Magliocca et al., 2006; Drukker et al., 2002; 
Li et al., 2004). However, with the differentiation of ES cells into EBs and teratomas, 
expression of MHC class I gene increases 4 and 10 fold, respectively (Drukker et al., 
2002). Immune responses induced by ES cells increase over time after 
allotransplantation (Swijnenburg et al., 2005). However, MHC class II molecule is neither 
expressed nor upregulated on the surface of undifferentiated or differentiated cells, as 
well as after stimulated with interferon γ (IFNγ; Drukker et al., 2002). Similarly, CD80 and 
CD86 expression is undetected either during differentiation or treatment with IFNγ (Li et 
al., 2004; Drukker et al., 2006).  
 
Considering the low to absent expression of MHC class I and absence of MHC class II 
expression on mouse ES cells, they fail to stimulate T cell proliferation in mixed 
lymphocyte reaction (MLR) (Bonde and Zavazava 2006). Furthermore, mouse ES cells 
are resistanted to lysis by allogeneic cytotoxic T lymphocytes (CTL) and are only lysed 
by CTL at a moderately level after treatment with IFNγ (Bonde and Zavazava 2006). 
Even lymphocytic choriomeningitis virus (LCMV) infected mouse ES cells or EBs showed 
resistence to LCMV specific CTL lysis (Abdullah et al., 2007). In contrast, mouse ES 
cells pulsed with ovalbumin peptide were efficiently lysed by ovalbumin-specific T cell 
receptor (TCR) transgenic T cells (Dressel et al., 2009).  
 
NK cells, one of the components of innate immunity, represent the first line of defense. It 
has been reported that rat ES cells were killed by NK cells due to their low expression of 
MHC class I molecules and their expression of ligands for the activating NK receptor 
NKG2D (Dressel et al., 2008). However, mouse ES cells showed no or low potential of 
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being killed by NK cells (Koch et al., 2008). As allogeneic human ES cells were immune-
rejected by recipient (Boyd et al., 2012), most recently Rong et al exhibited a new 
approach to avoid immune responses. Human ES cells were engineered to constitutively 
express cytotoxic T lymphocyte antigen 4-immunoglobulin fusion protein and 
programmed death ligand-1, and such cells were immune protected by inhibiting T cell 
activities. Cells derived from these engineered human ES cells showed immune 
tolerance in humanlized mice (Rong et al., 2014). However, this approach also increases 
the risk of oncogenic transformation or might cause an accumulation of pathogenic 
viruses, due to the immune-privileged characteristics of these engineered cells (Willinger 
and Flavell 2014). In summary, this new strategy facilitates the application of allogeneic 
human ES cells in a clinical setting. Yet, a more safe and effective method to exploit 
allogeneic human ES cells and their derivatives warrants further investigation.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.4. Possible antigen presentation pathways in allograft rejection. 
a: In the direct pathway donor APC present alloantigens, which are recognized by recipient T cells. 
b: Recognition of allo-MHC molecules directly by recipient T cells.  
c: After transplantation alloantigens are recognized by recipient APC and presented to recipient T 
cells (Kadereit and Trounson 2011). 
 
Immune protective molecules expression 
Further to low expression of MHC antigens and costimulatory molcules, immune-
modulatory molecules secreted by ES cells represent another contribution for their 
reduced immunogenicity. It has been reported that serine protease inhibitor 6 (serpin-6), 
an endogenous inhibitor of granzyme B, was highly expressed in mouse ES cells. 
Serpin-6 showed a protection of ES cells from lysing by CTL (Abdullah et al., 2007). Anti-
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inflammation cytokines were found to be highly expressed in mouse ES cells and 
showed an inhibition of T cell proliferation and antigen presenting cell (APC) maturation 
(Koch et al., 2008). The impaction of ES cells on T cell activation and polarization was 
likely through negatively regulating the protein kinase C-θ (Mohib et al., 2012). Other 
possible immune-modulatory molecules and their mechanisms related to the low 
immunogenicity of ES cells still need to be investigated. 
 
The expression of other immune-related factors  
Minor histocompatibility antigens (miHA) are peptides derived from normal cellular 
proteins that show polymorphism among individuals. miHA is sufficiently antigenic to be 
recognized by CTL (Wallny and Rammensee 1990). Mouse ES cells showed vigorous 
rejection upon transplantion into MHC-matched mice, simply due to the different 
expression of miHA (Robertson et al., 2007). Further to expression of MHC and miHA 
proteins, culture conditions can also contribute to immune responses. It has been shown 
that human ES cells cultured with animal-derived feeder cells or serum induced immune 
responses, because of incorporation of animal sialic acid residues or serum components 
(Martin et al., 2005; Hisamatsu-Sakamoto et al., 2008). However, to what extent the 
miHA, culture conditions or other potential factors will affect the immunogenicity of ES 
cells remain to be determined.  
1.4.2 Immunogenicity of iPS cells and their derivatives 
Autologous iPS cells are believed to be particularly appealing as a cell source for 
personalized regenerative therapies due to their expected ability to bypass immune 
rejection (Nishikawa et al., 2008). However, recent studies challenged this view by 
showing immune rejection of mouse fibroblast derived iPS cells upon syngeneic 
transplantation as measured by teratoma formation and lymphocytic infiltration (de 
Almeida et al., 2014; Zhao et al., 2011). These findings are in contrast with the results 
from Guha et al. where syngeneic iPS cells showed 100% graft survival (Guha et al., 
2013).  
 
Follow-up studies evaluated the immunogenicity of specific differentiated cells derived 
from iPS cells in a syngeneic setting (Araki et al., 2013; Guha et al., 2013;de Almeida et 
al., 2014). Cardiomyocytes derived from iPS cells in vitro cause significant levels of T cell 
infiltration after syngeneic transplantation (Araki et al., 2013). However, other studies 
indicated that syngeneic iPS cell-derived cells elicited only minimal immune responses or 
induced tolerogenic immune responses following transplantation (Araki et al., 2013; 
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Guha et al., 2013;de Almeida et al., 2014). However, skin and BM cells used for 
transplantation developed in iPS cell-derived chimeric mice (Araki et al., 2013), where 
immunogenic or abnormal cells might get eliminated or induced to acquire immune 
tolerance (Fu 2014; Scheiner et al., 2014). Guha et al. transplanted terminally 
differentiated cells of all three germ layers into syngeneic hosts and there was no 
immune response as measured by T cell infiltration and graft survival (Guha et al., 2013). 
However, in this study the transplantation site (subcapsular renal space) is prone to 
induce immune tolerance due to the presence of immature DC (Coates et al., 2004; Fu 
2014). In addition, so far only three cell types (endothelial cells, hepatocytes and 
neuronal cells) differentiated from iPS cells were investigated and it is currently unclear, 
which cell type contains leftover of the reprogramming process and thus immunogenicity 
(Cao et al., 2014). Furthermore, Morizane et al used nonhuman primate as a model to 
test the immunogenicity of neural cells derived from autologous and allogeneic iPS cells 
(Morizane et al., 2013). They found that neural cells derived from autologous iPS cells 
elicited only a minimal immune response compared to allogeneic iPS cells. 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5. Immunogenicity of autologous iPS cells. 
a: Syngeneic ES cells grow into teratomas following transplantation into mice and cause immune 
tolerance.  
b: Autologous iPS cells derived from fetal fibroblasts elicit an unexpected immune rejection 
(Apostolou and Hochedlinger 2011).  
 
An interesting question is what might cause immunogenicity of iPS cells and their 
differentiated progeny? The somatic cell type used for reprogramming might impact on 
the immunogenicity of iPS cells (Boyd et al., 2012). Human umbilical cord mesenchymal 
cells were used for iPS cell generation, as mesenchymal cells exhibit immune-
modulatory properties (Liu et al., 2013). It was found that neural progenitors derived from 
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these iPS cells showed lower immunogenicity compared to those from fibroblast-derived 
iPS cells. This study indicates that both iPS cells and their differentiated progenies retain 
some epigenetic memory after cell reprogramming and subsequent differentiation. 
However, in this study the immunogenicity of iPS cells and their derived cells has only 
been investigated in vitro and several questions remained: (i) in vivo immunogenicity of 
these iPS cells and their derived cells; (ii) the effect of passage number on the 
immunogenicity of iPS cells and their derivatives; (iii) the effect of other immune-
privileged somatic cell types on the immunogenicity of iPS cells and their derivatives. 
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1.5 Objectives and aims 
The first establishment of iPS cells by introduction of four reprogramming factors 
(OSKM) stimulated great prospects for regenerative medicine. Most of the studies focus 
on the mechanisms, methods and efficiency for iPS cell generation, differentiation ability 
of iPS cells and their potential application for disease modelling. However, recent studies 
indicated that undifferentiated iPS cells were immune rejection upon syngeneic 
transplantation, which challenged the application of autologous iPS cells and their 
differentiated progeny for personalized medicine. Although follow up studies support the 
safety of syngeneic iPS cells and their differentiated derivatives, we should be alert 
about their possible immunogenicity. Several factors might influence the immunogenicity 
of iPS cells, such as the somatic cell type used for iPS cell generation (Boyd et al., 2012), 
in vitro culture conditions (Scheiner et al., 2014), cell types used for transplantation and 
the transplantation sites (Cao et al., 2014; Scheiner et al., 2014). It has been reported 
that somatic memory affects the characteristics and functions of iPS cells to some extent 
(Polo et al., 2010; Bar-Nur et al., 2011), thus indicating the importance of selecting the 
most appropriate starting cell population for iPS cell generation. 
 
The objective of this study is to determine the influence of the parental somatic cell type 
on the immunogenicity of resulting iPS cells. To answer this question, immune-privileged 
Sertoli cells were used to generate iPS cells (Ser-iPS cells) and compared their 
immunogenicity with mouse embryonic fibroblast derived iPS cells (MEF-iPS cells). The 
immunogenicity of Ser-iPS cells was examined by both in vivo syngeneic transplantation 
and in vitro co-culture with T cells. Immune response was investigated by flow cytometry, 
qRT-PCR and immunohistochemistry. 
 
As iPS cells have potential risk of tumorigenesis, researchers investigated alternative 
reprogramming methods, such as transdifferentiation. Here MEF from Vav-
iCre/ROSA26R-fGFP reporter mice (Vav-MEF) were used for transdifferentiation into 
hematopoietic cells by overexpression of Oct4 and Oct4 combined with Bmi1. Flow 
cytometry analysis was used to investigate the expression of hematopoietic cell markers. 
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2 MATERIALS 
2.1 Instruments 
Instruments Manufactures 
Centrifuges Heraeus (Hanaw, Germany); Eppendorf Centrifuge 5424; 
Sigma 2K15 
Flow cytometer BD FACS Canto II 
Incubator Heraeus (Hanaw, Germany) 
Polymerase chain 
reaction (PCR) 
Thermocycler (Eppendorf, Hamburg, Germany) 
Quantitative real-time 
RT-PCR (qRT-PCR) 
StepOnePlus™ Real-Time PCR System  
(Applied Biosystems, Foster City, CA, USA) 
Microscopes Axiovert 200; AMG EVOS®fl; Leica DMIL; Leica DMRX 
Gel documentation 
system 
Biorad Gel doc X systerm (Bio-Rad, Hercules, CA, USA) 
CASY cell counting and 
analysis system 
Schärfe Systems (Schärfe Systems, Reutlingen, Germany) 
Gentle MACS 
Dissociator 
Miltenyi Biotec 
Nanodrop 
Spectrophotometer 
Thermo Scientific 
Haemacytometer Brand 
 
Computers Software 
MAC Mini Word, Excel, Power Point, Adobe Reader, Tierbase, FlowJo 7.6.5 for 
Mac 
Mac PC Endnote X6, FlowJo 7.6.5 and 8.7.2 for Mac, Adobe Photoshop, 
Microsoft Office 2011 for Mac, GraphicConverter X, GraphPad Prism 
5, MeV_4_8, Origin Pro 8.0, StepOne™ software (version 2.1) 	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2.2 Mouse strains 
 Strain name Source 
BL6 wild type (wt) C57BL/6 (B6) In-house breeding 
Rosa26R-fGFP Rosa26R-CAG-
farnesylted-eGFP 
A kind gift of Emma L. Rawlins, 
Gurdon Institute, Cambridge, UK 
(Rawlins et al., 2009) 
Vav-iCre Vav-iCre A kind gift of Dimitris Kioussis, 
London, UK and Meinrad Busslinger, 
IMP, Vienna, Austria (de Boer et al., 
2003; Kwon et al., 2008) 
Vav-iCre/Rosa26R-
fGFP 
B6-tg (Vav-
iCre)(Rosa26R-fGFP) 
In-house breeding 
NOD-Scid NOD-(scid)(IL2Rg) tm In-house breeding 
CD1  In-house breeding 
2.3 Antibodies 
FACS antibodies 
Target protein Clone Label Company 
CD4 GK1.5  PE-conjugated eBioscience 
CD44 IM7 eFluor450-conjugated eBioscience 
CD4 RM4-5 FITC-conjugated eBioscience 
CD25 PC61.5 APC-conjugated eBioscience 
Foxp3 FJK-16s PE-conjugated eBioscience 
CD45 30-F11 APC-Cy7-conjugated BD 
F4/80 CI:A3-1 Pacific Blue-conjugated Abcam 
F4/80 BM8 APC-conjugated eBioscience 
CD19 MB19-1 PE-Cy5-conjugated eBioscience 
CD11b M1/70 eFluor450-conjugated eBioscience 
CD8 53-6.7 PE-Cy7-conjugated eBioscience 
 
 
 
 
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  MATERIALS	  
	  	   25	  
Immunofluorescence antibodies 
Primary antibodies 
Target protein Clone Dilution Company 
Oct4 C-10 1:200 Santa Cruz Biotechnology 
SSEA1 480 1:200 Santa Cruz Biotechnology 
 
Secondy antibodies Dilution Company 
Alexa594 goat anti-mouse Ig (H+L) 1:300 Life Technologies 
2.4 Vector and Plasmid Constructs 
Backbone Constructs Source 
pMX Oct4 (mouse) Add Gene 
Sox2 (mouse) Add Gene 
Klf4 (mouse) Add Gene 
c-Myc (mouse)  Add Gene 
GFP (mouse) Add Gene 
pMSCV Bmi1 (mouse) From our lab 
2.5 Chemicals and solutions 
If not stated otherwise, all chemicals were purchased from Sigma-Aldrich, Merck or 
Fluka in analytical grade quality. 
Chemicals Manufactures  
Anti-CD4 MicroBeads Miltenyi Biotec 
4’,6-Diamidino-2-Phenylindole (DAPI) Vector Laboratories 
Mounting solution Dako 
DNA ladder (Gene Ruler 1kb and 100bp ladder plus) Fermentas 
2.6 Consumable materials 
Materials Manufactures 
Cell strainer (70 µm, 40 µm) BD Falcon™ 
MACS separation columns (MS) Miltenyi Biotec 
Gentle MACS M tubes Miltenyi Biotec 
FACS tubes Sarstedt 
qRT-PCR plate Applied Biosystems 
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Other cell culture dishes, disposable pipettes and centrifuge tubes were purchased from 
Eppendorf, Brand, Nunc, TPP or BD FalconTM. 
2.7 Kits 
The following kits were used in molecular and biochemical assay: 
Kits Manufactures 
NucleoSpin tissue kit Macherey-Nagel 
NucleoSpin RNA II kit Macherey-Nagel 
NucleoBond Xtra Maxi kit Macherey-Nagel 
High-Capacity cDNA Reverse Transcription Kit Applied Biosystems 
Fast SYBR Green master mix Applied Biosystems 
Alkaline phosphates kit Stemgent 
Mouse Regulatory T Cell Staining Kit eBioscience 
VECTASTAIN® ABC KIT Vector Laboratories Ltd 
2.8 Primers for PCR 
Primers for genotyping 
Gene Sequences information (5’ è 3’) 
 
Annealing 
temp. 
Cycle 
no. 
Cre for GCCTGCCCTCCCTGTGGATGCCACCT 65°C 36 
Cre rev GTGGCAGAAGGGGCAGCCACACCATT 
Rosa26 for CACTTGCTCTCCCAAAGTCG 60°C 30 
Rosa26 rev TAGTCTAACTCGCGACACTG 
CAG GTTATGTAACGCGGAACTCC 
for: forward primer; rev: reverse primer 
 
Primers for RT-PCR 
Gene Sequences information (5’ è 3’) References 
Dazl for GCACTCAGTCTTCATCAGCAAC (Kinarm Ko et al., 2009) 
Dazl rev CTATCTTCTGCACATCCACGTC 
Vasa for CTTGCAGAGATGTTCAGCAGAC (Ko et al., 2009) 
Vasa rev CTCCAAGAGCTTGCTCTCTCTC 
Hsd3β6 for TGGACAAGTTCTTCAGACCAGA  
Hsd3β6 rev TCTCCTTCCAACACTGTCACC  
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TGFβ1 for TGAGTGGCTGTCTTTTGACG (Dufour et al., 2008) 
TGFβ1 rev TTGGTATCCAGGGCTCTCC 
Gata4 for CCCTACCCAGCCTACATGG (Kyrönlahti et al., 2011) 
Gata4 rev GAGCTGGCCTGCGATGTCTGAGTG 
Rex1 for CAGCAGCTCCTGCACACAGA  
Rex1 rev GATCCGCAAACACCTGCTTT  
Rex3 for GAGCGGAGCAGGTCTGAGAA  
Rex3 rev GACTCCATTACTCCTGGGCCT  
Dppa4 for CATTGGGGGTAGGAACACGGAAGG  
Dppa4 rev TGCCCCAAGTGTGTTCATAA  
Sox2 for F-TAGAGCTAGACTCCGGGCGATGA  
Sox2 rev R- TTGCCTTAAACAAGACCACGAAA  
GAPDH for GGGGTGAGGCCGGTGCTGAGTAT  
GAPDH rev CATTGGGGGTAGGAACACGGAAGG  
 
Primers for qRT-PCR 
Gene Sequences information (5’ è 3’) References 
Oct4 for TCTTTCCACCAGGCCCCCGGCTC (Takahashi et 
al., 2006) Oct4 rev TGCGGGCGGACATGGGGAGATCC 
Flk1 for CTTCTGGCTCCTTCTTGTCATTG  
Flk1 rev TCATTGGCCCGCTTAACG  
Nanog for TCTGGGAACGCCTCATCAAT  
Nanog rev GGAGAGGCAGCCTCTGTGC  
MHCα for CATGGCATCACTCTTCTCTACCTATGC  
MHCα rev TACCACTGACACCGGTATCA  
AFP for TCAGCGAGGAGAAATGGTCC  
AFP rev ATGAAAATGTCGGCCATTCC  
β-actin for CACCAGTTCGCCATGGATG  
β-actin rev GCCGTTGTCGACGACCAG  
Nestin for AGAGTCAGATCGCTCAGATCC  
Nestin rev GCAGAGTCCTGTATGTAGCCAC  
CD3 for TCGTCACTGTCTAGAGGGCA  
CD3 rev CCTCCTAGCTGTTGGCACTT  
CD4 for CAAGCGCCTAAGAGAGATGG  
CD4 rev CACCTGTGCAAGAAGCAGAG  
CD8b for GATGGTCTTTGGGACAGGG (Rui et al., 
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CD8b rev ATGCCAGCAGAAGCAGGAT 2012) 
CD11c for CTGGATAGCCTTTCTTCTGCTG (Shaul et al., 
2010) CD11c rev GCACACTGTGTCCGAACTC 
B200 for AAGAGTTGTGAGGCTGGCAC  
B220 rev GCTCAAACTTCTGGCCTTTG  
Mac1 for GTTTGTTGAAGGCATTTCCC  
Mac1 rev ATTCGGTGATCCCTTGGATT 
Gr1 for TGCCCCTTCTCTGATGGATT (Doloff et al., 
2012) Gr1 rev TGCTCTTGACTTTGCTTCTGTGA 
Zg16 for CATCACCGCCTTCCGTAT (Zhao et al., 
2011) Zg16 rev CGTTGAAACTTGTGCCTGA 
Hormad1 for CCAGATTACCAACCACCAG (Zhao et al., 
2011) Hormad1 rev TGAAAAGGTGTTGGGACT 
Sox9 for AGTACCCGCATCTGCACAAC (Svingen et 
al., 2007) Sox9 rev TACTTGTAATCGGGGTGGTCT 
AMH for GGTGGAGGCTCTTGGAACTT  
AMH rev GGGAGACTGGAGAACAGCAG  
ABP for CTCAGGGCCTGGTCTATGTC  
ABP rev TCTCTCCCTTGGGGCTTTAC  
ArginaseⅠ for AACACGGCAGTGGCTTTAACC Kropf et al., 
2005 ArginaseⅠ rev GGTTTTCATGTGGCGCATTC 
CD3-ζ chain for TCAATCTAGGGCGAAGAGAGG  
CD3-ζ chain rev GGGCATCACAGGTGTCCTT  
Foxp3 for CGAAAGTGGCAGAGAGGTATTGA (Mohib et al., 
2012) Foxp3 rev ACTGTCTTCCAAGTCTCGTCTGAA 
IFNγ for GAAAATCCTGCAGAGCCAGA (Mohib et al., 
2012) IFNγ rev TGAGCTCATTGAATGCTTGG 
IL4 for CGAGCTCACTCTCTGTGGTG  
IL4 rev TGAACGAGGTCACAGGAGAA  
MHC class I for CCAGACGAAAATATCTCAGCG  
MHC class I rev GGGTTGATGATGCTCCTGTT  
MHC class II for CAACCGTGACTATTCCTTCC Biswas et al., 
2012 MHC class II rev CCACAGTCTCTGTCAGCTC 
CD80 for GGCAAGGCAGCAATACCTTA Shaul et al., 
2010 CD80 rev CTCTTTGTGCTGCTGATTCG 
CD86 for TCTCCACGGAAACAGCATCT Shaul et al., 
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2.9 Reagents, cytokines and growth factors for cell culture 
Reagents Manufactures 
DMEM (4.5g/L high Glucose) GIBCO® Invitrogen Cell Culture 
RPMI-1640 GIBCO® Invitrogen Cell Culture 
DMEM/F12 (1:1) GIBCO® Invitrogen Cell Culture 
Phosphate buffered saline (PBS) GIBCO® Invitrogen Cell Culture 
Penicillin-streptomycin (P/S) GIBCO® Invitrogen Cell Culture 
L-Glutamin GIBCO® Invitrogen Cell Culture 
Non-essential amino acid (NEAA) GIBCO® Invitrogen Cell Culture 
β-mercaptoethanol GIBCO® Invitrogen Cell Culture 
HEPES GIBCO® Invitrogen Cell Culture 
Trypsin-EDTA GIBCO® Invitrogen Cell Culture 
Collagenase, Type IV GIBCO® Invitrogen Cell Culture 
Fetal calf serum (FCS) for ES/iPS cells Lonza, Cologne, Germany 
FCS for cell lines Invitrogen Life Technologies 
FCS for HSC Invitrogen Life Technologies 
  
Cytokines and growth factors 
Stem cell factor (SCF) Recombinant mouse SCF or 1% 
supernatant of SCF producing CHO KLS C6 
cells 
Hyper-interleukin 6 (IL-6) A kind gift of S. Rose-John, Kiel University, 
Kiel, Germany 
Flt3 ligand Purchased from Peprotech 
Insulin-like growth factor 1 (IGF1, long 
range, human) 
Sigma-Aldrich 
Human LIF Peprotech  
Matrigel™  BD Bioscience 
 	  
CD86 rev CTTACGGAAGCACCCATGAT 2010 
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2.10 Medium for cell culture 
Cells  Medium  
Sertoli cells DMEM/F12 (1:1); 2 mM L-Glutamine; 100 U/ml P/S; 
10% FCS (for cell lines) 
MEF DMEM (4.5g/L high Glucose); 2 mM L-Glutamine; 100 
U/ml P/S; 10% FCS (for cell lines) 
293T cells DMEM (4.5g/L high Glucose); 2 mM L-Glutamine; 100 
U/ml P/S; 10% FCS (for cell lines) 
T cells RPMI-1640; 0.05 mM β-mercaptoethanol; 
2 mM L-Glutamine; 100 U/ml P/S; 0.1 mM NEAA; 10% 
(heat-inactivated) FCS for HSC 
ES/iPS cells  DMEM (4.5g/L high Glucose); 0.1 mM β-
mercaptoethanol; 2 mM L-Glutamine; 100 U/ml P/S; 0.1 
mM NEAA; 25 mM HEPES; 15% (heat-inactivated) FCS 
for ES cells 
HSC  RPMI-1640; 0.05 mM β-mercaptoethanol; 2 mM L-
Glutamine; 100 U/ml P/S; 10% (heat-inactivated) FCS 
for HSC 
Freezing medium for ES/iPS 90% FCS (Lonza); 10% dimethyl sulfoxide (DMSO)  
Freezing medium for cell 
lines 
90% FCS (for cell lines); 10% DMSO  
2.11 Buffers 
Buffer Recipes Buffer Recipes 
Red blood cell 
(RBC) lysis buffer 
150 mM NH4Cl 
100 mM NaHCO3 
10 mM EDTA in 
ddH2O 
pH adjusted to 7.4 
10×TBE 0.89 M Tris/HCl 
0.89 M boric acid 
20 mM EDTA 
4% 
paraformaldehyde 
(PFA), 
4% 
paraformaldehyde in 
PBS 
pH 7.3 
2 M CaCl2 
 
CaCl2: 184.9 g 
H2O: 100 ml 
 
Flow cytomentry 
buffer 
1% bovine serum 
albumin (BSA, 
Hepes 
stock 
Hepes: 11.92 g 
H2O: 50 ml 
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Fraction V, Sigma) 
in PBS 
solution  
MACS buffer 0.5% FBS  
EDTA (0.5 M): 5 ml 
PBS: 500 ml 
2×HBS NaCl (280 mM): 1.64 g 
Hepes: 5 ml stock solution 
Na2HPO4: 0.021 g 
pH 7.08 
Carboxyfluorescein 
succinimidyl ester 
(CFSE) labeling 
buffer 
5% FCS in PBS 
 
0.05% 
PBST 
0.05% Tween20 in PBS 
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3 METHODS 
3.1 Mice 
Vav-iCre mice, Rosa26R-fGFP mice and B6 wt mice are bred at the Central Animal 
Facility of RWTH Aachen University Hospital. Heterozygote mice for Rosa26R-fGFP 
were crossed with transgenic mice expressing Cre under the control of Vav promoter 
(Vav-iCre × Rosa26R-fGFP+/-) to generate homozygote (Vav-iCre/Rosa26R-fGFP+/+) 
offspring (see below 4.6.1). All mice were maintained under specific pathogen free 
conditions in the Central Animal Facility of RWTH Aachen University Hospital. All animal 
experiments were approved by the local authorities (Bezirksregierung Köln) in 
compliance with the German animal protection law. 
3.2 MEF preparation 
Primary MEF were prepared from day 13.5 pregnant Vav-iCre/Rosa26R-fGFP mice and 
B6 mice. Briefly, day 13.5 pregnant mice were sacrificed. The uterus was removed and 
opened to extract the fetal bag, which contains embryo and placenta. The following steps 
were performed under sterile conditions. Fetal bags were put into a Petri dish and 
embryos were picked out. Embryos were washed twice with 1× P/S and 1×PBS, 
respectively. The head, liver and inner organs were removed with forceps. The 
carcasses were washed once with 1×PBS and 0.05% trysin/EDTA solution, respectively, 
and then finely minced with scissors and incubated with 0.05% trypsin at 37°C for 10 min. 
Pipetted up and down several times to homogenize the suspension. MEF medium was 
added to terminate the digestion. The cells were centrifuged at 1000 rpm for 5 min and 
plated at 2 ×106 cells per 10 cm dish. MEF medium was refreshed every 2-3 days and 
cells were split when confluent. Cells were frozen either as vital cells or after γ-ray 
inactivation. 
3.3 Sertoli cell preparation 
Testis of B6 mice (age: 7-10 days) was de-capsulated and primary Sertoli cells were 
isolated as described before (Yang and Han 2010) with modifications. Briefly, testis was 
de-capsulated with forceps, washed once with PBS and dispersed in 0.1% collagenase 
(type IV) at 37°C for 5 min. The tubules were collected and centrifuged at 200 g for 5 min 
followed by two washes with PBS to remove testicular interstitial cells and blood cells. 
Collected tubules were then treated with 0.05% trypsin-EDTA (0.5 ml/testis) for another 5 
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min at 37°C and pipetted up and down to disperse the testicular cells. Subsequently, 
fetal bovine serum was added to a final concentration of 10% (v/v) to terminate the 
digestion. Fragments were filtered through a 40 µm cell strainer and washed twice with 
DMEM/F12. The cell pellet was re-suspended in DMEM/F12 supplemented with 10% 
(v/v) FCS, 2 mM L-Glutamine, 100 U/ml P/S and plated onto tissue culture dishes. After 
overnight culturing, floating cells were removed by refreshing medium. Obtained Sertoli 
cells were frozen in liquid nitrogen (LN2) for later use when cells were 90-95% confluent. 
3.4 Plasmid preparation 
Competent E.coli cells were prepared by CaCl2 method and stored at -80°C. Strain 
DH5α was used for amplifying plasmids. About 100 µl competent cells were thawed on 
ice and mixed with plasmid DNA (50 ng), then incubated on ice for 30 min. The cells 
were heat shocked at 42°C for 90 sec followed by incubating another 2 min on ice. Then, 
the cells were added with 800 µl lysogeny broth (LB) medium and incubated at 37°C for 
1 hour in the shaker. Proper amount of the cells (about 200 µl) were plated on pre-
warmed LB-agar plates with antibiotics. The plates were incubated at 37°C for overnight. 
Single colony was manually picked and amplified by culturing for plasmid preparation.  
3.5 Cell transfection 
293T cells 
293T cells were grown in DMEM medium supplemented with 10% FCS, 2 mM L-
Glutamine and 100 U/ml P/S and incubated at 37°C with 5% CO2. 293T cells were split 
before they were 80% confluent. To split 293T cells, cells were washed once with PBS 
and incubated with 0.05% trypsin-EDTA for 3 min. Trypsin treatment was terminated with 
293T medium and appropriate numbers of cells were plated in cell culture dishes. 
 
Retrovirus preparation 
One day prior to transfection, 293T cells were plated at 3.5×106 cells per 10 cm dish and 
evenly distributed. Medium was refreshed one hour before transfection. Transfection was 
carried out using calcium phosphate/DNA co-precipitation method. Plasmid DNA, 
calcium chloride and 2×HBS buffer were prepared as below. 
 
DNA solution was added dropwise into HBS buffer with continuously bubbling. The 
HBS/DNA mixture was added dropwise onto the cells and distributed evenly. Medium 
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was changed 24 hours after infection. Retrovirus was harvested 72 hours post-
transfection and the supernatant was passed through 0.45 µm filter for further use. 
Retrovirus preparation Volume 
Target construct (12 µg)  
Envelope pVPack-Eco (8 µg)  
Gag, pol pVPack GP (8 µg) 500 µl 
2 M CaCl2 62.5 µl  
Water up to 500 µl  
2×HBS  500 µl 
3.6 Reprogramming somatic cells to hematopoietic/iPS cells 
3.6.1 Transdifferentiation Vav-MEF to hematopoietic cells 
Purify Vav-MEF with MACS or FACS sorting 
Vav-MEF were prepared from Vav-iCre/Rosa26R-fGFP reporter mice, which expressing 
GFP reporter gene under the control of Vav promoter (see 3.1 and below 4.6.1). Vav-
MEF were isolated as described before (see 3.2) and passaged once. Single cells were 
collected by treating with 0.05% trypsin. For MACS selection, Vav-MEF were passed 
through MACS MS column (CD45 MicroBeads, Miltenyi Biotec, Bergisch Gladbach, 
Germany) and depletion of CD45+ cells was used to remove hematopoietic cells. For 
FACS sorting, Vav-MEF were selected as CD45-GFP- cells to remove hematopoietic 
cells (FACSAria, BD Biosciences). Then, an aliquot of purified cells were tested for purity 
by flow cytometry (FACSCanto II). Purified Vav-MEF were frozen in LN2 for further use. 
 
Transdifferentiation Vav-MEF to hematopoietic cells 
One day before transfection, MACS or FACS sorted Vav-MEF were seeded into 6-well 
plates at a density of 1×105 cells per well. For transdifferentiation, pMX based retrovirus 
expressing reprogramming factor Oct4 and pMSCV based retrovirus expressing Bmi1 
were used. pMX-GFP retrovirus was used as a control to assess virus titer. Retrovirus 
suspension was added onto Vav-MEF in the presence of 8 µg/ml polybrene (PB, Sigma-
Aldrich). MEF medium was refreshed 2 days after infection and then changed to HSC 
medium with the addition of cytokines 4 days after infection. The following cytokines 
were used for transdifferentiation: 
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SCF 30 U/ml 1% supernatant of stably transfected 
CHO KLS C6 cells 
Hyper-IL-6 5 ng/ml A kind gift of S. Rose-John (Kiel 
University,  Kiel, Germany) 
Flt3 ligand 25 ng/ml Peprotech 
IGF-1 long range 
(human) 
40 ng/ml Sigma 
 
Medium was changed every 2 days. When non-adherent cells emerged, the supernatant 
was collected, centrifuged, re-suspended with fresh HSC medium and then put back into 
the Petri dish.  
3.6.2 Reprogramming Sertoli cells and MEF into iPS cells 
One day before reprogramming, B6 Sertoli cells and B6 MEF were seeded into 6-well 
plates at a density of 1×105 cells per well. pMX retroviral vectors expressing 
reprogramming factors OSKM (Kim et al., 2008) were used for iPS cell generation. 
Sertoli cells and MEF were infected with retrovirus expressing either four factors (OSKM) 
or three factors (OSK) in the presence of 8 µg/ml PB. Two days after infection, medium 
was changed with Sertoli cell and MEF medium, respectively. Five days later, medium 
was replaced with ES medium in the presence of LIF (hereafter referred to as complete 
ES medium). Colony-liked cells emerged at around day 10 after retrovirus transduction 
and were manually picked at day 14 and transferred into 96-well plates. Single cells were 
obtained by treating with 0.05% trypsin and further cultured in 24-well plates and then in 
6-well plates on MEF feeder cells with complete ES medium. 
3.7 ES and iPS cell differentiation in EB assays 
ES cells and iPS cells were grown in complete ES medium. For spontaneous 
differentiation in vitro, undifferentiated ES cells and iPS cells were subjected to EB 
assays. Briefly, ES cells and iPS cells were trypsinized into single cells and plated onto 
0.1% gelatin-coated Petri dishes for 40 min to remove feeder cells. ES cells and iPS 
cells were collected and counted by hemocytometer measurement. Cells were 
suspended with appropriate volume of ES medium without LIF. EBs were generated by 
hanging drop with 500 cells per 20 µl drops in an inverted bacterial Petri dish. Three 
days later, EBs were collected and cultured in bacterial Petri dishes for another 3 days. 
Subsequently, EBs were put onto 0.1% gelatin-coated Petri dish for further differentiation. 
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3.8 Alkaline phosphatase and immunofluorescence staining 
For alkaline phosphatase (AP) staining, ES cells and iPS cells were seeded in 6-well 
plates one day in advance. Then cells were washed once with PBS and performed AP 
staining (see 2.7; Stemgent) according to the manufacturer’s instruction. Cells were 
covered with PBS and images were acquired with Leica microscopy. 
 
For immunofluorescence staining, ES cells and iPS cells were grown on gelatin-coated 
coverslips and fixed with 4% PFA (20 min, room temperature, RT). For Oct4 staining 
cells were permeabilized with 0.1% TX-100 (30 min, RT). Cells were washed twice with 
0.5% BSA/PBS buffer and incubated with primary antibodies (14-16 hours, 4°C). After 
washing, secondary antibody, Alexa594 goat anti-mouse Ig (H+L) was used (see 2.3; 
1:300, 1 hour, RT; Life Technologies, Carlsbad, CA). DAPI (0.1 µg/mL, 30 min) was used 
to stain nuclei. Samples were mounted with mounting solution (Dako, Glostrup, 
Denmark) and images were acquired with Axiovert 200 microscopy (Carl Zeiss, Jena, 
Germany). The following primary antibodies were used: Oct4 and SSEA1 (see 2.3; 
1:200; Santa Cruz Biotechnology, Santa Cruz, CA). 
3.9 Teratoma assay 
For teratoma assay, ES cells and iPS cells were trypsinized to single cells and feeder 
cells were removed by attaching to gelatin-coated Petri dishes for 40 min. 1×106 cells 
were injected into the rear thigh of NOD-Scid mice and B6 male mice. Four weeks later, 
recipient mice were sacrificed and teratomas were excised. Half of the teraotoma was 
fixed in 4% PFA, embedded in paraffin and sectioned for histological analysis. The other 
half of the teratoma was frozen in -80°C for RNA isolation. Frequency of teratoma 
formation was assessed as number of injections relative to teratomas formed. 
3.10 HE and immunohistochemical staining 
Hematoxylin and eosin (HE) staining and immunohistochemical staining of teratoma 
sections were performed at IZKF Immunohistochemistry Core Facility (RWTH Aachen 
University Hospital, Aachen, Germany). Briefly, paraffin-embedded teratoma sections 
were cut, de-waxed and rehydrated. Some of the sections were directly used for HE 
staining.  
 
For immunohistochemical staining, the primary antibody employed was rabbit polyclonal 
anti-CD3 antibody (1:200 dilution; Abcam, Cambridge, UK). Then, teratoma sections 
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were incubated with diluted biotinylated secondary antibody solution (30 min) followed by 
30 min incubation with VECTASTAIN® ABC Reagent (Vector Laboratories, Peterborough, 
UK). Subsequently, sections were incubated in peroxidase substrate solution until 
desired staining intensity developed. With each set of staining process, spleen was 
included as positive control. 
3.11 Preparing DNA and RNA 
Isolation of mouse tail genomic DNA, bacterial plasmid, total RNA were all performed 
with commercial kits (see 2.7). To get RNA from teratomas, tissues were first 
homogenized by gentleMACS Dissociator using specific gentleMACS M tubes. 
Homogenized samples were centrifuged (2000 g, 1 min), proceeded with RNA isolation 
according to manufacture’s instruction (NucleoSpin RAN II kit, Macherey-Nagel). The 
quality and concentration of RNA were determined with Nanodrop 1000 (Thermo 
Scientific, Wilmington, DE).  
3.12 Polymerase chain reaction  
Reverse transcription 
To evaluate the level of gene expression, cDNA was synthesized by reverse 
transcription. mRNA was reverse-transcribed using High Capacity cDNA Reverse 
Transcription Kit (Applied Biosystems, Carlsbad, CA) according to manufacturer’s 
instruction. Briefly, 1 µg of total RNA was used as template, together with the reaction 
mixture from the kit to perform the reverse transcription. The standard thermal cycle was 
25°C for 10 min, 37°C for 2 hours and 75°C for 5 min. 
 
PCR reaction 
PCR is used to amplify a specific region of DNA strand. Primers were designed 
containing sequence complementary to the target region. A typical PCR reaction mixture 
was: 
 
cDNA sample 50 ng in 2 µl 
10×buffer (NH4)2SO4 2 µl 
MgCl2 (25 mM) 2 µl 
for primer (10 mM) 0.5 µl 
rev primer (10 mM) 0.5 µl 
dNTP (10 mM each) 0.5 µl 
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Recombinant Taq DNA Polymerase (Fermentas) 0.5 µl 
(dd) water 12 µl 
Total volume 20 µl 
 
The PCR reaction was performed on thermal cycling machine (Eppendorf, Hamburg, 
Germany). A standard reaction scheme was: 
Initiation  95°C 5 min  
Denaturation 95°C 30 sec  
Annealing Gene-specific annealing 
temperature  
1 min Gene-specific 
cycle numbers 
Extension 72°C 1 min  
Final extension 72°C 5 min  
Termination  4°C ∞  
 
Quantitative real-time RT-PCR 
qRT-PCR enables quantification for one or more specific sequences in a cDNA sample 
which corresponds to the transcription level of target genes. We performed qRT-PCR 
reaction on StepOneTM Real-Time PCR system (Applied Biosystems, Carlsbad, CA). All 
the reagents and plastic plates for qRT-PCR were purchased from Applied Biosystems. 
Data are represented in heatmap format (MultiExperiment Viewer MeV_4_8, 
http://www.tm4.org.) with fold change in gene expression normalized to β-actin. The 
typical recipe for qRT-PCR reaction was: 
Fast SYBR Green Master mix 10 µl 
for primer (10 mM) 0.5 µl 
rev primer (10 mM) 0.5 µl 
cDNA sample  50 ng (5 µl after 1:5 dilution) 
(dd) water 4 µl 
Total volume 20 µl 
 
The qRT-PCR program was carried out as below:  
 Temperature Time Number of cycles 
Enzyme activation 95°C 20 sec 1 
Denaturation  95°C 3 sec 
40 
Annealing and extension 60°C 30 sec 
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3.13 Mouse splenic CD4 T cell isolation 
B6 mouse spleens (age: 6-10 weeks) were removed aseptically and washed once with 
1×P/S and PBS, respectively. Then, spleens were gently homogenized with the stamp of 
a 1 ml syringe and passed through 40 µm cell strainer. Cells were then washed with PBS, 
stained with CD4 MicroBeads (Miltenyi Biotec, Bergisch Gladbach, Germany; 15 min, 
4°C) and put into MS column (Miltenyi Biotec) for MACS selection. CD4 T cells were 
collected and cultured in T cell medium for further use. The purity of CD4 T cells was 
determined by flow cytometry (FACSCanto II).  
3.14 Flow cytometry 
Cells were collected, washed once with flow cytometry buffer and incubated with specific 
antibodies (1:100 dilution, 30 min, 4°C). Then, cells were washed and re-suspended with 
proper volumn of flow cytometry buffer. The following antibodies were used: APC-Cy7-
conjugated CD45, APC-conjugated F4/80, PE-conjugated CD4, FITC-conjugated CD4, 
APC-conjugated CD25 and PE-conjugated Foxp3. Results were analyzed using Flowjo 
(Tree Star Inc., Ashland, OR, USA). FACS sorting was performed with FACSAria (BD 
Bioscience) at RWTH Aachen University Hospital (kindly operated by Christiane Becker, 
Institute for Biomedical Engineering, Department of Cell Biology, RWTH Aachen 
University, Aachen, Germany). 
3.15 T cell proliferation assay 
CD4 T cells were resuspended in CFSE labeling buffer (5% FCS in PBS) and labeled 
with 2.5 uM cell tracking dye CFSE (10 min, RT). After washing, 5×104 CD4 T cells were 
cultured in triplicates in 96-well U-bottom microtiter cell plates (Costar) with or without 
phorbol myristate acetate (PMA, 25 ng/ml) and ionomycin (0.02 mM). Co-culture with T 
cells was performed with undifferentiated cells (day 0-5) or EBs (day 12-17 of 
differentiation) from iPS cells or ES cells at 2:1 ratio. After 5 days of co-culture, 
proliferation of CD4 T cells was analyzed by assessing the dilution of CFSE signal using 
flow cytometry (FACSCanto II). The assay was carried out in duplicates for n=3 
independent experiments. 
3.16 Regulatory T cell assay 
CD4 splenic T cells were isolated from B6 mice and pretreated with PMA (25 ng/ml) and 
ionomycin (0.02 mM) to active T cells (16 hours). Then, T cells were collected and co-
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cultured with undifferentiated iPS cells or with EBs of iPS cells (day 12-17 of 
differentiation) at 2:1 ratio. After 5 days of co-culture, T cells were harvested and stained 
for surface markers CD4 and CD25 (30 min, 4°C). Subsequently, cells were fixed and 
permeabilized using the Foxp3 fixation/permeabilization buffer and intracellular Foxp3 
(eBioscience) staining was carried out according to manufacturer’s instruction. FACS 
analysis was performed with FACSCanto II. 
3.17 Statistic analysis 
Results are given as mean ± standard derivation. Statistical analysis was performed 
using unpaired Student's t-test. P values below 0.05 were considered to be statistically 
significant.  
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4 RESULTS 
4.1 Generation and characteristics of Ser-iPS cells 
To generate iPS cells, Sertoli cells were isolated from B6 mice, and transfected with pMX 
retroviral vectors expressing either four factors OSKM or three factors OSK. iPS cells 
derived from B6 MEF (MEF-iPS cells) were generated accordingly and used as control. 
Sertoli cell derived iPS cells (Ser-iPS cells) were injected into B6 mice to test their in vivo 
immunogenicity in teratoma assay. B6 MEF-iPS cells and B6 ES cells (JM8, kindly 
provided by Konstantinos Anastassiadis, BIOTEC, Technical University Dresden) were 
taken as controls (Figure 4.1). 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1. Schematic representation of Ser-iPS cell generation and teratoma assay in B6 
mice. 
Sertoli cells were isolated from day 7-10 immature B6 male mice. MEF were isolated from day 
13.5 pregnant B6 mice. iPS cells were generated by transfection with retrovirus expressing either 
four factors OSKM or three factors OSK, hereafter referred to as Ser-iPS cells and MEF-iPS cells, 
respectively. B6 Ser-iPS cells were injected into syngeneic B6 male mice to test their teratoma 
formation ability. B6 MEF-iPS cells and B6 ES cells are shown as controls. OSKM: Oct4, Sox2, 
Klf4 and c-Myc; OSK: Oct4, Sox2 and Klf4. 
4.1.1 Sertoli cell isolation and culture 
Sertoli cells were isolated from day 7-10 newborn B6 male mice as described above 
(Methods 3.3). Immature animals are chosen as the source of Sertoli cells, because they 
produce Sertoli cells with relatively high cell yield and purity, and they are also well-
differentiated cell type (Nicholls et al., 2011). Furthermore, Sertoli cells from immature 
animals are well-characterized model for in vitro culture of primary Sertoli cells (Nicholls 
et al., 2011).  
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Primary Sertoli cells were cultured in Sertoli cell medium and became confluence 2-3 
days later. In culture, primary Sertoli cells were similar to fibroblast in morphology (Figure 
4.2A). After one passage, Sertoli cells stretched out, formed a monolayer, showed more 
cytoplasm compared to peritubular cells and exhibited an irregular shape (Figure 4.2A; 
Ahmed et al., 2009) with much lower growth rate compared to primary Sertoli cells.  
Figure 4.2. Isolation of Sertoli cells from immature B6 mice. 
A: Sertoli cells were isolated from day 7-10 B6 mice and were split once when they were 
confluent. P0: passage 0; P1: passage 1. Scale bar represents 800 µm. 
B: RT-PCR analysis for the purity of in vitro cultured Sertoli cells. Sertoli cells were collected at 
passage 1 after becoming confluent. Germ cells and Leydig cells, which were freshly isolated 
from adult B6 mice, were used as positive controls. B6 ES cells were used as a positive control. 
GAPDH were served as loading control.  
 
Purity of in vitro cultured Sertoli cells was analyzed by RT-PCR. Sertoli cells expressed 
Gata4, a specific marker for Sertoli cells (Doyle et al., 2012). They were negative for 
Oct4 and Nanog, two markers expressed in spermatogonial stem cells (Guan et al., 
2006), as well as Dazl1 (Lifschitz-Mercer et al., 2002) and Vasa (Toyooka et al., 2000), 
two specific markers for germ cells. Sertoli cells failed to express Hsd3β6 (Ma et al., 
2004), a specific marker for Leydig cells (Figure 4.2B). Since spermatogonial stem cells 
are difficult to isolate and culture in vitro, mouse B6 ES cells, which express Oct4 and 
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Nanog, were used as a positive control. These data indicate that Sertoli cells isolated 
from immature B6 male mice can survive and proliferate during in vitro culture with a 
much higher purification. 
4.1.2 Generation and characteristics of Ser-iPS cells 
Generation of Ser-iPS cells 
iPS cells were generated by transfection with traditional Yamanaka vectors (Takahashi 
and Yamanaka 2006; Kim et al., 2008). Sertoli cells were prepared for transfection as 
described above and infected with pMX retroviral vectors expressing either four factors 
OSKM or three factors OSK (Methods 3.6.2). MEF-iPS cells were generated from B6 
MEF accordingly and used as a control. pMX retroviral vector expressing GFP reporter 
gene was used as a positive control to monitor the transfection efficiency. Two days after 
infection, GFP fluorescence was observed with microscopy. Lower efficiency of Sertoli 
cell infection was observed compared to MEF according to the GFP fluorescence (Figure 
4.3). This may be due to the slower proliferation efficiency of Sertoli cells after one 
passage than MEF during in vitro culture. Because retroviral vectors used here require 
actively dividing cells during transfection (Cooray et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.3. Transfection efficiency of Sertoli cells with retroviral vectors. 
Sertoli cells were infected with GFP-expressing retrovirus to determine the efficiency of 
transfection (upper panel). Corresponding B6 MEF are shown as control (lower panel). Images 
were taken 2 days after infection. PH: phase contrast. Scale bar represents 1000 µm.  
 
After 2-3 days of infection, Sertoli cell medium was replaced with complete ES medium. 
About 8 days after infection, clusters of cells were observed with a higher nuclear-to-
cytoplasmic ratio and an increased proliferation rate. These clusters kept proliferating 
and clustering. About 10 days after retrovirus induction, multilayered compact Ser-iPS 
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cell clones with clearly marked borders, which were similar to mouse ES cell clones, 
emerged (Figure 4.4). About 12 days after induction, Ser-iPS cell clones were manually 
picked, trypsinized into single cells and kept in culture on feeder cells with complete ES 
medium. 
Figure 4.4. Bright-field images depicting reprogramming of mouse Sertoli cells into iPS 
cells. 
Sertoli cells clustered together with an increased proliferation rate and altered morphology after 
transfection with retrovirus and finally became Ser-iPS cell clones. Scale bar represents 1000 µm.  
 
Pluripotency of Ser-iPS cells 
Ser-iPS cell clones (86 clones) and MEF-iPS cell clones (65 clones) were picked and 
cultured on feeder cells. Good clones were selected for expanding according to their 
proliferation rate and morphology during in vitro culture (Ser-iPS cells: 19 clones; MEF-
iPS cells: 17 clones). Among these clones, three representative Ser-iPS cell clones and 
two representative MEF-iPS cell clones, which exhibited proliferation and differentiation 
potential similar to ES cells, were selected for further analysis (Table 1). For selected 
three Ser-iPS cell clones, Ser-iPS 1 refers to 4F iPS cells (OSKM, clone 1) and Ser-iPS 
2 and 3 refer to 3F iPS cells (OSK, clones 2 and 3, respectively); for selected two MEF-
iPS clones, MEF-iPS 1 and 2 refer to 4F iPS cells (OSKM, clone 1) and 3F iPS cells 
(OSK, clone 2), respectively. 
Table 4.1. Numbers of Ser-iPS cell and MEF-iPS cell clones picked, expanded and selected 
for further analysis 
 Picked clones Expanding clones Clones used for  
further analysis 
Ser-iPS (OSKM) 80 16 1 
Ser-iPS (OSK) 6 3 2 
MEF-iPS (OSKM) 60 14 1 
MEF-iPS (OSK) 5 3 1 
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In vitro cultured Ser-iPS cells showed typical ES cell morphology. They are presented as 
homogenous clusters of small, tightly packed cells, bright at the edge, and have similar 
grown rates to ES cells in vitro (Figure 4.5A). These clones showed a high level of AP 
expression, as determined by AP staining (Figure 4.5B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.5. Ser-iPS cells in vitro culture and AP staining. 
A: In vitro cultured Ser-iPS cells. MEF-iPS cells and ES cells were used as controls. 
Representative phase contrast images are shown. Scale bar represents 400 µm. 
B: AP expression in Ser-iPS cells. Ser-iPS cells were grown on MEF feeder cells. AP staining was 
performed one day after passage. Cells were fixed and stained with substrate to AP according to 
the manufacturer’s instruction. MEF-iPS cells and ES cells, controls as in (A). All Ser-iPS cells 
and MEF-iPS cells are passage 9-15 (early-passage). Scale bar represents 200 µm.  
 
Furthermore, immunofluorescence staining was performed to test the expression of 
pluripotency genes, Oct4 (nuclear localization) and SSEA1 (cell surface localization). 
These two pluripotency markers were highly expressed in Ser-iPS cells, similar to MEF-
iPS cells and ES cells (Figure 4.6A, B). Pluripotency gene expression in Ser-iPS cells 
was further analyzed by RT-PCR. The endogenous Oct4, Sox2, Nanog, Rex1, Rex3 and 
Dppa4 genes were activated and expressed at a similar level to those of MEF-iPS cells 
and ES cells (Figure 4.7). 
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Figure 4.6. Immunofluorescence staining of pluripotency gene markers in Ser-iPS cells. 
A-B: Oct4 and SSEA1 expression in undifferentiated Ser-iPS cells. Oct4 and SSEA1 staining, red 
color. DAPI (blue) is used for the nuclei staining. Ser-iPS cells organized in tight compact clones 
similar to clones of undifferentiated MEF-iPS cells and ES cells. All Ser-iPS cells and MEF-iPS 
cells are passage 9-15 (early-passage). Scale bar represents 35 µm. 
 
 
 
 
 
 
 
 
 
Figure 4.7. Pluripotency gene expression in Ser-iPS cells by RT-PCR. 
RNA was isolated from Ser-iPS cells. RT-PCR was performed to examine the expression of 
pluripotency genes Oct4, Sox2, Nanog, Rex1, Rex3 and Dppa4 in these Ser-iPS cells. MEF-iPS 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
RESULTS 
	  	   49	  
cells and ES cells were taken as positive controls. MEF were used as negative control. All Ser-
iPS cells and MEF-iPS cells are passage 9-15 (early-passage). GAPDH was served as a loading 
control. 
 
All together, Ser-iPS cells displayed pluripotent characteristics similar to MEF-iPS cells 
and ES cells, such as similar morphology, AP activity and expression of endogenous 
pluripotency genes. Thus, Ser-iPS cells represent bona fide pluripotent cells.  
 
Differentiation of Ser-iPS cells 
Although Ser-iPS cells are very similar to ES cells in pluripotency, another important 
criteria to evaluate iPS cells is their differentiation capability. The classical methods to 
assess iPS cell differentiation potential are EB assay in vitro and teratoma assay in 
immunodeficient mice in vivo. For in vitro differentiation, EB assay was performed as 
described before (Methods 3.7). Day 14 EBs were collected, RNA was isolated and 
employed to qRT-PCR. Undifferentiated iPS cells and ES cells were used as controls.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.8. EB assay of Ser-iPS cells. 
EB assay of Ser-iPS cells was performed by hanging drop. Their differentiation potential was 
examined by qRT-PCR with both undifferentiated cells and day 14 differentiated EBs. The results 
are presented in heatmap format according to their fold change normalized to β-actin. Green 
represents low expression and red represents high expression. The mRNA level in 
undifferentiated ES cells was arbitrarily set to 1. All Ser-iPS cells and MEF-iPS cells are passage 
9-15 (early-passage). 
 
The expression of several pluripotency and differentiation genes was tested, such as 
Oct4, Nanog (pluripotency gene markers), Nestin, Flk1, MHCα and AFP (differentiation 
gene markers). The qRT-PCR result was presented in heatmap format (Figure 4.8). After 
14 days of differentiation, Ser-iPS cells downregulated endogenous pluripotency gene 
expression, Oct4 and Nanog, compared to undifferentiated Ser-iPS cells. The expression 
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of differentiation gene markers, such as Nestin (neural cell marker), Flk1 (early 
mesoderm marker), MHCα (cardiomyocyte marker) and AFP (endoderm marker) was all 
upregulated compared to undifferentiated Ser-iPS cells. Thus, Ser-iPS cells have the 
ability to differentiate into all three germ layers in vitro, which was similar to that of MEF-
iPS cells and ES cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.9. Teratoma assay in NOD-Scid mice. 
1×106 Ser-iPS cells were injected into NOD-Scid mice subcutaneously. One mouse with two 
injection sites was used for each clone. MEF-iPS cells and ES cells were used as controls. Four 
weeks later, mice were sacrificed and teratomas were excised. The samples were fixed in 4% 
PFA and stained with HE. Representative images of ectoderm, mesoderm and endoderm are 
shown. All Ser-iPS cells and MEF-iPS cells are passage 9-15 (early-passage). HE: haematoxylin 
and eosin. Scale bar represents 200 µm. 
 
For iPS cell in vivo differentiation, teratoma assay is a standard method. After injection 
into immunodeficient mice, pluripotent stem cells form teratomas with cell derivatives of 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
RESULTS 
	  	   51	  
all three germ layers. To examine the differentiation potential of Ser-iPS cells, teratoma 
assay was performed in NOD-Scid mice. 1×106 undifferentiated Ser-iPS cells in 100 µl 
DMEM in the presence of Matrigel (BD Biosciences; DMEM/Matrigel: 4/1) were injected 
into the rear thigh of NOD-Scid mice. B6 MEF-iPS cells and ES cells were injected 
accordingly and taken as controls. Teratomas were collected 4 weeks after injection, 
fixed in 4% PFA, embedded in paraffin and sectioned for HE staining. The result 
indicates that Ser-iPS cells can form teratomas contained cell derivatives of all three 
germ layers, including neural rosette (ectoderm), cartilage (mesoderm) and glandular 
epithelium (endoderm) (Figure 4.9).  
 
Overall, all these data indicate successful reprogramming of Sertoli cells into pluripotent 
state and Ser-iPS cells exhibit pluripotent differentiation potential. These results suggest 
that Sertoli cells were successfully reprogrammed into iPS cells by overexpressing 
reprogramming factors. Obtained Ser-iPS cells display pluripotent characteristics, such 
as typical ES-liked morphology and growth in vitro, high AP expression, endogenous 
pluripotency genes, differentiation into all three germ layers by EB assay in vitro and by 
teratoma assay in NOD-Scid mice. Thus, these Ser-iPS cells are qualified as bona fide 
iPS cells and can be used for further analysis. 
4.2 Teratoma assay in B6 mice 
Immunogenicity of iPS cells and iPS cell-derived cells is detected in vivo in teratoma 
assay (Koch et al., 2008; Zhao et al., 2011). Teratomas comprise a broad spectrum of 
differentiated cells of all three germ layers and thus allow assessing in vivo 
immunogenicity of iPS cells and of their differentiated progeny simultaneously. Thus, to 
investigate whether iPS cells derived from immune-privileged Sertoli cells show reduced 
immunogenicity, undifferentiated Ser-iPS cells were syngeneically injected into B6 mice 
for teratoma assay. The frequency of teratoma formation served as a measure of 
immunogenicity of iPS cells and iPS cell-derived cells: high teratoma formation reflects 
low immunogenicity and low or no teratoma formation indicates high immunogenicity and 
consequently immune rejection. 
4.2.1 Teratoma assay in B6 mice  
To investigate the immunogenicity of Ser-iPS cells, 1×106 B6 Ser-iPS cells were injected 
into male B6 mice. B6 MEF-iPS cells and B6 ES cells were injected accordingly and 
used as controls. For each iPS cell clone, 10 mice with 20 injection sites were used for 
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teratoma assay. Four weeks after injection, mice were sacrificed and teratomas were 
excised. Half of the teratoma was fixed in 4% PFA, embedded in paraffin and sectioned 
for further analysis. The other half of the teratoma was frozen in -80°C for RNA isolation. 
Upon syngeneic transplantation, Ser-iPS cells showed the potential to form teratomas of 
different sizes (Figure 4.10A) with cell derivatives of all three germ layers, including 
neural rosettes (ectoderm), cartilage (mesoderm) and glandular epithelium (endoderm), 
similar to those of MEF-iPS cells and ES cells (Figure 4.10B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.10. Ser-iPS cell teratoma formation in B6 mice. 
A: Ser-iPS cell teratomas in B6 mice. 1×106 Ser-iPS cells were injected into B6 mice 
subcutaneously and teratomas were collected four weeks after injection. Representative images 
of B6 mice with two teratomas at rear thigh (left panel) and the corresponding teratoma collected 
from B6 mice (right panel) are shown. Teratomas from Ser-iPS cells (OSKM, clone 1) are shown. 
White arrows indicate the position of teratomas. Ruler is used to measure the size of obtained 
teratomas. 
B: Tissue structures of Ser-iPS cell teratomas from B6 mice. MEF-iPS cell and ES cell teratomas 
were used as controls. Tissue structures of all three germ layers were observed in teratomas from 
B6 mice. Representative images of ectoderm, mesoderm and endoderm from Ser-iPS cell (OSKM, 
clone 1), MEF-iPS cell (OSK, clone 2) and ES cell teratomas are shown. All Ser-iPS cells and 
MEF-iPS cells are passage 9-15 (early-passage). Scale bar represents 200 µm. 
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The efficiency of teratoma formation by iPS cells and ES cells in B6 mice is shown in 
Table 4.2. Ser-iPS cells formed teratomas at an efficiency of 80%, while ES cells had 
90% teratoma formation frequency. But the incidence of teratoma formation for MEF-iPS 
cells was only about 20% (Table 4.2). Frequency of teratomas formed in B6 mice is also 
shown as histogram. Ser-iPS cells have a much higher incidence of teratoma formation 
(80%) than MEF-iPS cells (20%) and the incidence of teratoma formation for Ser-iPS 
cells is comparable to ES cells (90%; Figure 4.11A). There was no significant difference 
in the size of teratomas formed by Ser-iPS cells and MEF-iPS cells, while the size of 
teratomas formed by ES cells was larger (Figure 4.11B). The average size of teratomas 
formed in B6 mice was about 1-1.5 cm. 
Table 4.2 Efficiency of teratoma formation in B6 mice 
Clones Nr. Teratomas Nr. Injection sites Frequency of teratoma 
formation 
ES 18 20 90% 
Ser-iPS 48 60 80% 
MEF-iPS 8 20 20% 
 
 
 
 
 
 
 
 
 
 
Figure 4.11. Number and size of teratomas formed by Ser-iPS cells in B6 mice. 
A: Numbers of teratomas formed by Ser-iPS cells are summarized as histogram. Teratomas from 
MEF-iPS cells and ES cells were used as controls. For Ser-iPS cells and MEF-iPS cells, 30 and 
20 mice, respectively, were used, and for ES cells, 10 mice were used. 
B: Size of teratomas formed by Ser-iPS cells. Teratomas from MEF-iPS cells and ES cells were 
used as controls in (A). Ser-iPS cells and MEF-iPS cells in (A) and (B) refer to average values of 
all three Ser-iPS cell clones and two MEF-iPS cell clones. All Ser-iPS cells and MEF-iPS cells are 
passage 9-15 (early-passage). Unpaired Student’s t-test was used to analyze the statistical 
significance. * indicates P < 0.05, ** indicates P < 0.01. Bars represent mean ± standard deviation. 
 
Collectively, iPS cells or ES cells form teratomas with cell derivatives of all three germ 
layers upon syngeneic injection into B6 immunocompetent mice. In addition, Ser-iPS 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
RESULTS 
	  	   54	  
cells form more teratomas upon syngeneic transplantation than MEF-iPS cells. These 
data suggest that iPS cells derived from immune-privileged Sertoli cells elicit less 
immune responses and thus permit more efficient teratoma formation in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.12. CD3 T cell infiltration in Ser-iPS cell teratomas formed in B6 mice. 
Immunohistochemical staining for CD3 T cells was performed in Ser-iPS cell teratomas. 
Teratomas of MEF-iPS cells and ES cells are shown as controls. CD3 staining in spleen was 
taken as a positive control. Brown cells represent CD3 positive T cells. Representative images of 
CD3 T cell infiltration in teratomas from Ser-iPS cells (OSKM, clone 1), MEF-iPS cells (OSK, 
clone 2) and ES cells are shown. All Ser-iPS cells and MEF-iPS cells are passage 9-15 (early-
passage). Scale bar represents 200 µm.	  
4.2.2 T cell infiltration and tissue damage and necrosis in teratomas 
Although both iPS cells and ES cells formed teratomas in B6 mice, the incidence of 
teratoma formation was very different. To further investigate the in vivo immunogenicity 
of Ser-iPS cells, immunohistochemical staining of B6 teratoma sections was performed. 
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Teratoma sections were prepared as described before (Methods 3.9), and analyzed for 
CD3 T cell infiltration. CD3 staining was performed at IZKF Immunohistochemistry Core 
Facility as described in Methods 3.10. As expected, Ser-iPS cell teratomas showed 
lower CD3 T cell infiltration than those of MEF-iPS cells. Low CD3 T cell infiltration in 
Ser-iPS cell teratomas was similar to those of ES cell teratomas (Figure 4.12). 
Furthermore, Ser-iPS cell teratomas showed less tissue damage and necrosis compared 
to MEF-iPS cell teratomas by HE staining. The reduced tissue damage and necrosis in 
Ser-iPS cell teratomas was similar to ES cell teratomas (Figure 4.13). 	  
 
 
 
 	  
Figure 4.13. Tissue damage and necrosis in teratomas from B6 mice. 
Tissue damage and necrosis was detected in teratomas formed by both iPS cells and ES cells in 
B6 male mice. Representative images of tissue damage and necrosis in teratomas from Ser-iPS 
cells (OSKM, clone 1), MEF-iPS cells (OSK, clone 2) and ES cells are shown. All Ser-iPS cells 
and MEF-iPS cells are passage 9-15 (early-passage). Scale bar represents 200 µm. 
4.2.3 Gene expression of different immune cell types in teratomas 
Different immune cell types are involved in immune responses upon syngeneic 
transplantation. CD4 T helper cells recognize antigens presented by MHC class II 
molecules and produce cytokines that help the activities of other immune cells. Cytotoxic 
CD8 T cells are activated by antigens presented by MHC class I molecules and are very 
efficient in lysis of target cells bearing these antigens. B cells, another main type of 
lymphocytes, work mainly by secreting antibodies into the body’s fluids. DC are antigen-
presenting cells, which present processed antigens on the surface to other immune cells. 
Macrophages are generated from differentiated monocytes and protect the body by 
ingesting and destructing harmful cells.  
 
By immunohistochemical staining, low CD3 T cell infiltration in Ser-iPS cell teratomas 
was observed. Other immune cell infiltration in teratomas was further examined by qRT-
PCR, such as for T cells (CD3, CD4 and CD8), DC (CD11c), B cells (B220), 
macrophages (Mac1) and granulocytes (Gr1). Ser-iPS cell teratomas exhibited much 
lower CD3, CD11c and B220 gene expression than MEF-iPS cells (Figure 4.14). The low 
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expression of these genes in Ser-iPS cell teratomas was comparable to that in ES cell 
teratomas. CD3 gene expression analyzed by qRT-PCR was consistent with the result of 
CD3 immunohistochemical staining. Expression of CD4 and CD8 T cell markers was 
also lower in Ser-iPS cell teratomas compared to that of MEF-iPS cells, but this did not 
reach statistical significance. However, there was no significant difference in the 
expression of macrophage and granulocyte markers (Mac1 and Gr1, respectively). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14. Gene expression of different immune cells in Ser-iPS cell teratomas. 
Ser-iPS cell teratomas were first cut into small pieces and homogenized by gentleMACS 
Dissociator using specific gentleMACS M tubes. Then RNA was isolated and qRT-PCR was 
performed. Teratomas from MEF-iPS cells and ES cells were taken as controls. Relative gene 
expression was normalized to β-actin. Average mRNA level in ES cell teratomas was arbitrarily 
set to 1. The mRNA level in spleen was used as a positive control. The number of B6 teratomas 
analyzed: Ser-iPS cells, n=19; MEF-iPS cells, n=8; ES cells, n=10. Average values of Ser-iPS cell 
1, 2 and 3 and MEF-iPS cell 1 and 2 are as in Figure 4.11. All Ser-iPS cells and MEF-iPS cells 
are passage 9-15 (early-passage). * indicates P < 0.05 (unpaired Student’s t-test). Bars represent 
mean ± standard deviation. 
 
Overall, these data indicate that syngeneic Ser-iPS cells have a higher incidence to form 
teratomas with less tissue damage and necrosis than syngeneic MEF-iPS cells. 
Furthermore, Ser-iPS cell teratomas exhibit lower T cell, DC and B cell infiltration than 
those of MEF-iPS cells. Thus, syngeneic Ser-iPS cells have reduced immunogenicity in 
vivo compared to MEF-iPS cells and showed low immune cell infiltration, which is 
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consistent with less tissue damage and necrosis. 
4.3 T cell in vitro co-culture  
Tissue destruction in teratomas is T cell dependent (Zhao et al., 2011) and Ser-iPS cell 
teratomas showed low T cell infiltration and tissue damage and necrosis. In addition, 
CD4 T lymphocytes play a more important role than CD8 T lymphocytes during immune 
rejection (Swijnenburg et al., 2008). Thus, the impact of Ser-iPS cells on CD4 T cell 
proliferation and Treg profile was examined in vitro. EB assay represents the in vitro 
equivalent of teratoma formation in vivo. Therefore, Ser-iPS cells were subjected to EB 
assays (12 days), dissociated and co-cultured with CD4 T cells in T cell medium. 
4.3.1 T cell proliferation assay 
For T cell proliferation assay in vitro, CD4 MACS selected B6 splenocytes were labeled 
with CFSE and co-cultured with undifferentiated Ser-iPS cells and EBs of Ser-iPS cells 
(day 12-17 of differentiation). The proliferation of CD4 T cells was analyzed by assessing 
the dilution of CFSE signal 5 days after co-culture by flow cytometry (FACSCanto II; 
Figure 4.15). Proliferation of CD4 T cells was calculated as the percentage of cells that 
divided at least once. 
 
 
 
 
 
 
 
 
 
 
Figure 4.15. Schematic representation of CD4 T cell proliferation assay in vitro. 
Splenic CD4 T cells from B6 mice were acquired by purification with MACS. EBs of Ser-iPS cells 
obtained by hanging drop were kept in suspension culture for 6 days followed by another 6 days 
of adherent culture in gelatin-coated Petri dishes. Both undifferentiated and EBs (day 12-17 of 
differentiation) of Ser-iPS cells were trypsinized into single cells, filtered through 40 µm cell 
strainer and co-cultured with CFSE labeled CD4 T cells at a ratio of 1:2. After 5 days of co-culture, 
proliferation of CD4 T cells was examined by assessment the dilution of CFSE signal using flow 
cytometry.  
 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
RESULTS 
	  	   58	  
Purified CD4 T cells were obtained by MACS with MS tubes and their purity was 
immediately examined by flow cytometry. The purity of CD4 T cells after MACS selection 
was about 95.5% (Figure 4.16).  
 
 
 
 
 
 
 	  
 
Figure 4.16. Purity of CD4 T cells after MACS selection. 
CD4 T cells were purified by MACS and stained with PE-conjugated CD4 for 30 min. Purity of 
freshly isolated CD4 T cells was examined by flow cytometry. Unstained CD4 T cells were used 
as control. SSC: Side Scatter. 
 
For CD4 T cell co-culture experiments, Ser-iPS cells were not inactivated, to mimic 
pluripotent stem cell differentiation in vivo in teratoma assays. For undifferentiated cells, 
there was no significant difference in the percentage of dividing T cells between Ser-iPS 
cells and MEF-iPS cells, as well as ES cells (all about 15-20%; Figure 4.17A). About 
70% of T cell proliferated in positive control (CD4 T cells stimulated with PMA and 
ionomycin). However, when co-cultured with EBs of Ser-iPS cells, MEF-iPS cells and ES 
cells (day 12-17 of differentiation), the proliferation of CD4 T cell was very different. The 
percentage of dividing CD4 T cells co-cultured with EBs of Ser-iPS cells (day 12-17 of 
differentiation) was about 20%, similar to that of ES cells. However, the percentage of 
dividing T cells was about 50% after co-culture with EBs of MEF-iPS cells. T cell 
proliferation was low when co-cultured with Sertoli cells and MEF (Figure 4.17B). The 
results shown in Figure 4.17B were summarized as histogram (n=3). Significantly, lower 
T cell proliferation was observed after co-culture with EBs of Ser-iPS cells than MEF-iPS 
cells. However, no significant difference of T cell proliferation was observed between 
EBs of Ser-iPS cells and ES cells (Figure 4.17C). 
 
Alltogether, no significant difference is obsevered in undifferentiated iPS cells and ES 
cells for their CD4 T cell stimulation potential. However, EBs of Ser-iPS cells exhibit 
significantly lower T cell stimulation potential in vitro compared to MEF-iPS cells, which 
very much relates to the reduced immunogenicity observed in teratoma assays. 
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Figure 4.17. CD4 T cell proliferation after co-culture with undifferentiated and EBs of Ser-
iPS cells (day 12-17 of differentiation). 
A: CD4 T cells co-cultured with undifferentiated Ser-iPS cells in T cell medium. MEF-iPS cells, ES 
cells, Sertoli cells and MEF were used as controls. T cells activated with PMA and ionomycin 
were employed as positive control. T cell proliferation refers to the percentage of dividing T cells 
after 5 days of co-culture. The results are summarized as histogram for n=3 independent 
experiments. Bars represent mean ± standard deviation. 
B: CD4 T cells co-cultured with EBs of Ser-iPS cells (day 12-17 of differentiation) in T cell medium. 
Representative images of T cell proliferation analyzed by flow cytometry are shown. Ser-iPS cells 
(OSKM, clone 1), MEF-iPS cells (OSKM, clone 1). The first peak on the right in each image 
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indicates undivided CD4 T cells with strong CFSE fluorescence signal and the other peaks on the 
left note the proliferating T cells as demonstrated by the decline of CFSE fluorescence intensity 
compared to the peak of non-dividing cells. The number in each image indicates the percentage 
of dividing cells. T cells activated with PMA and ionomycin, positive control as in (A). 
C: Summary of CD4 T cell proliferation showed in (B). Average values of Ser-iPS cell 1, 2 and 3 
and MEF-iPS cell 1 and 2 in (A) and (C) are as in Figure 4.11. All Ser-iPS cells and MEF-iPS cells 
are passage 9-15 (early-passage). The proliferation assay was carried out in duplicates for n=3 
independent experiments. T cells activated with PMA and ionomycin, positive control as in (A). * 
indicates P < 0.05; *** indicates P < 0.001. Bars represent mean ± standard deviation. 
4.3.2 Regulatory T cell assay 
Activation by PMA and ionomycin was first examined by measuring the T cell activation 
markers, CD25 and CD44. After one day of activation, T cells expressing CD25 and 
CD44 were 40% and 70%, respectively, and 2 days after activation, 50% T cells 
expressed these T cell activation markers. Afterwards, the percentage of activated T 
cells declined to 30% (Figure 4.18). This result suggests that CD4 T cells can be 
effectively activated by PMA and ionomycin after treatment for one day. 
Figure 4.18. Activation of CD4 T cells with PMA and ionomycin. 
CD4 T cells were activated with PMA and ionomycin for 3 days. The percentage of activated T 
cells was examined every day by flow cytometry for the T cell activation markers CD25 and CD44. 
Image summarizes the results of flow cytometry analysis. 
 
Regulatory T cells (Tregs) play an essential role in maintenance of immunologic 
tolerance by suppressing aggressive T cell response, preventing autoimmunity and 
delaying allograft rejection in several animal models (Shevach 2002; Asano et al., 1996; 
Kingsley et al., 2002). Sertoli cells can skew T cells towards a Treg profile and this 
represents one way how Sertoli cells generate an immune-privileged testicular 
environment (Dal Secco et al., 2008; Doyle et al., 2012). Therefore, the frequency of 
Tregs in co-cultures of CD4 T cells with Ser-iPS cells was examined by measuring the 
expression of CD4, CD25 and Foxp3 by flow cytometry. MEF-iPS cells and ES cells 
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were used as controls. Sertoli cells were taken as a positive control, since they skew T 
cells towards a Treg profile (Dal Secco et al., 2008). To avoid any influence of chemical  
Figure 4.19. Frequency of Tregs after co-culture with undifferentiated or EBs of Ser-iPS 
cells (day 12-17 of differentiation). 
A: Percentage of Tregs after co-culture with EBs of Ser-iPS cells (day 12-17 of differentiation). 
MEF-iPS cells, ES cells, Sertoli cells and MEF were used as controls. Activated T cells with PMA 
and ionomycin were taken as a further control. Representative images of Treg expression after 
co-culture with EBs of Ser-iPS cells are shown. Ser-iPS cells (OSK, clone 2), MEF-iPS cells (OSK, 
clone 2). The gate was set on CD4+ cells followed by CD25+ cells. T: activated T cells with PMA 
and ionomycin. Numbers depict the percentage of corresponding populations. 
B-C: Summarized results of flow cytometry analysis. Treg profile after co-culture with 
undifferentiated Ser-iPS cells (B) or with EBs of Ser-iPS cells (C) in T cell medium. MEF-iPS cells, 
ES cells, Sertoli cells, MEF and actived T cells with PMA and ionomycin were used as controls as 
in (A). T: activated T cells with PMA and ionomycin. Average values of Ser-iPS cell 1, 2 and 3 and 
MEF-iPS cell 1 and 2 in (B) and (C) are as in Figure 4.11. All Ser-iPS cells and MEF-iPS cells are 
passage 9-15 (early-passage). Bars represent mean ± standard deviation. Experiments was 
carried out in duplicates for n=2 independent experiments.  
 
reagents (PMA and ionomycin) on the properties of Ser-iPS cells, CD4 T cells were 
activated one day before co-culture. Then these compounds were removed by washing 
with PBS and T cell medium. Indeed, Sertoli cells showed an increase in Foxp3 
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expressing cells (20-26%), while T cells after co-culture with EBs of Ser-iPS cells, MEF-
iPS cells and ES cells showed Treg frequencies of about 6% (Figure 4.19A). 
Summarized results of flow cytometry analysis were further shown as histogram. No 
significant differences were observed for undifferentiated Ser-iPS cells, MEF-iPS cells 
and ES cells (Figure 4.19B) and also for EB-derived differentiated Ser-iPS cells, MEF-
iPS cells and ES cells (Figure 4.19C). Thus, Ser-iPS cells apparently do not possess the 
potential to convert T cells into a Treg phenotype. 
4.4 Generation of teratomas from late-passage Ser-iPS cells 
All results obtained so far are based on early-passage iPS cells (p9-15), at which stage 
somatic memory most likely still exists (Polo et al., 2010). Early-passage Ser-iPS cells 
showed reduced immunogenicity in following aspects: form teratoma at high frequency 
upon syngeneic transplantation, have lower T cell, DC and B cell infiltration in teratomas, 
exhibit less tissues damage and necrosis and less T cell stimulation potential at the EB 
stage. Thus, Ser-iPS cells appear to retain some somatic memory from immune-
privileged Sertoli cells, which might contribute to their reduced immunogenicity. 
 
Previous studies indicate that somatic memory will be erased upon extended passaging 
in vitro (Chin et al., 2009; Polo et al., 2010). Thus, the effect of extended culture periods 
on the immunogenicity of Ser-iPS cells was investigated. Late-passage Ser-iPS cells 
(p35-38) were injected into syngeneic mice to test their in vivo immunogenicity in 
teratomas assay. For each iPS and ES cell clone, 3 mice were used. Four weeks later 
teratomas were collected as before. Surprisingly, teratoma formation efficiency by late-
passage Ser-iPS cells was only about 50%, which was comparable to that of MEF-iPS 
cells (58.3%), but the incidence of teratoma formation by corresponding ES cells was 
100% (Table 4.3). No significant difference was observed for the number of teratomas 
formed by late-passage Ser-iPS cells and MEF-iPS cells. However, teratoma formation 
frequency for late-passage ES cells was much higher than those of iPS cells (Figure 
4.20A). In addition, given the size of teratomas formed by late-passage iPS cells and ES 
cells, no significant difference was observed (Figure 4.20B). For Ser-iPS cells, teratoma 
incidence of their late-passage (50%) was much lower than their early-passage 
counterparts (80%). While teratoma formation frequency of late (58.3%) and early-
passage (20%) MEF-iPS cells were reversed compare to Ser-iPS cells. However, no 
significantly different teratoma formation efficiency was found between late (100%) and 
early-passage (90%) ES cells (Figure 4.20C). 
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Table 4.3 Teratoma formation in B6 mice by late-passage Ser-iPS cells 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.20. Teratoma number and size formed by late-passage Ser-iPS cells in B6 mice. 
A: Number of teratomas formed by late-passage Ser-iPS cells was summarized as histogram. 
Late-passage MEF-iPS cells and ES cells were taken as controls. For Ser-iPS cells and MEF-iPS 
cells, 9 and 6 mice, respectively, were used; for ES cells, 3 mice were used. ** indicates P < 0.01. 
Bars represent mean ± standard deviation. 
B: Size of teratomas formed by late-passage Ser-iPS cells. Late-passage MEF-iPS cells and ES 
cells were taken as controls as in (A). Bars represent mean ± standard deviation. 
C: Comparison of teratoma formation frequency by early-passage (p9-15) and late-passage (p35-
38) Ser-iPS cells. Corresponding MEF-iPS cells and ES cells were taken as controls as in (A). 
Average values of Ser-iPS cell 1, 2 and 3 and MEF-iPS cell 1 and 2 in (A), (B) and (C) are as in 
Figure 4.11. Late-passage refers to passage 35-38. * indicates P < 0.05. Bars represent mean ± 
standard deviation. 
 
Taken together, late-passage Ser-iPS cells exhibit reduced teratoma formation efficiency 
compared to their early counterparts. This result suggests that the potential somatic 
memory in Ser-iPS cells might get lost during extended passaging in vitro. However, 
Clones Nr. Teratomas  Nr. Injection sites Frequency of 
teratoma formation 
ES 6 6 100% 
Ser-iPS 9 18 50% 
MEF-iPS 7 12 58.3% 
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teratoma formation efficiency of ES cells are independent of their passage number. 
Because ES cells come from inner cell mass of blastocyst they do not contain somatic 
memory. Thus, extended in vitro culture of Ser-iPS cells appears to impact on their 
immunogenicity. 
4.5 Possible molecules related to the reduced immunogenicity of Ser-iPS cells 
Late-passage Ser-iPS cells were found to lose their potential to form more teratomas 
upon syngeneic transplantation, which might be because their somatic memory gets lost 
and this leads to increased immunogenicity. Considering the reduced immunogenicity of 
early-passage Ser-iPS cells, two possibilities exist: one possibility is, that early-passage 
Ser-iPS cells preferentially differentiate into immune-privileged Sertoli cells. Another 
possibility is the early-passage Ser-iPS cells preserved some of Sertoli cell immune 
function and produced some immune-protective molecules to prevent immune rejection. 
4.5.1 Ser-iPS cells failed to re-differentiate into Sertoli cells 
To investigate whether early-passage Ser-iPS cells are more likely to re-differentiate into 
Sertoli cells, qRT-PCR analysis was performed. EBs (day 14 of differentiation) and 
teratomas of Ser-iPS cells were analyzed for Sertoli cell gene expression, such as sex 
determining region Y (Sry) box containing gene 9 (Sox9), anti-Müllerian hormone (AMH) 
and androgen-binding protein (ABP). MEF was used as negative control and Sertoli cells 
were taken as positive control.  
 
For the expression of Sox9 and AMH in both EBs and teratomas, no significant 
difference was observed between Ser-iPS cells and MEF-iPS cells, as well as ES cells, 
while these genes were highly expressed in Sertoli cells (Figure 4.21A, B). ABP was 
more abundantly expressed in EBs and teratomas of Ser-iPS cells, than in EBs and 
teratomas of MEF-iPS cells and ES cells. Whether this result suggests a preferred 
differention of Ser-iPS cells into Sertoli cells needs to be further investigated. 
4.5.2 Molecules related to immune response 
MHC and costimulatory molecules expression 
During teratoma formation in B6 mice, many immune-related molecules might be 
involved in the immune responses. MHC class I protein, which contributed to the low 
immunogenicity of ES cells, is expressed at a very low level on ES cells and moderately  
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Figure 4.21. Differentiation potential of EBs and teratomas from Ser-iPS cells. 
A-B: Expression of Sertoli cell markers in Ser-iPS cell EBs (left panel) and teratomas (right panel). 
B6 MEF were used as negative control and B6 Sertoli cells were taken as positive control. 
Relative gene expression was normalized to β-actin. The mRNA level in MEF was arbitrarily set to 
1. Average values of Ser-iPS cell 1, 2 and 3 and MEF-iPS cell 1 and 2 in (A) and (B) are as in 
Figure 4.11. All Ser-iPS cells and MEF-iPS cells are passage 9-15 (early-passage). Bars 
represent mean ± standard deviation.  
 
increased on their differentiated derivatives (Drukker et al., 2002). To investigate whether 
MHC or costimulatory molecule expression (CD80 and CD86) is responsible for the 
reduced immunogenicity of Ser-iPS cells, their expression on both undifferentiated and 
EBs of Ser-iPS cells was examined. From the qRT-PCR result, no significant difference 
was observed for the expression of MHC class I, MHC class II, CD80 and CD86 genes 
between Ser-iPS cells and MEF-iPS cells for both undifferentiated Ser-iPS cells (Figure 
4.22A) and EBs of Ser-iPS cells (day 14 of differentiation; Figure 4.22B). The expression 
of these molecules on iPS cells was similar to the expression on ES cells. These data 
suggest that levels of MHC and costimulatory molecules expression do not contribute to 
the different immunogenicity of Ser-iPS cells and MEF-iPS cells.  
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Figure 4.22. MHC and costimulatory molecules expression in undifferentiated and EBs 
(day 14 of differentiation) of Ser-iPS cells. 
A-B: Expression of MHC class I and II (MHC I and MHC II, respectively), costimulatory 
molecules CD80 and CD86 on undifferentiated (A) and EBs (day 14, B) of Ser-iPS cells. B6 MEF 
were used as negative control, and B6 splenocytes were taken as positive control. Relative gene 
expression was normalized to β-actin. The mRNA level in MEF was arbitrarily set to 1. Average 
values of Ser-iPS cell 1, 2 and 3 and MEF-iPS cell 1 and 2 in (A) and (B) are as in Figure 4.11. All 
Ser-iPS cells and MEF-iPS cells are passage 9-15 (early-passage). Bars represent mean ± 
standard deviation. 
 
Expression of molecules related to immunogenicity of pluripotent stem cells  
Expression of Hormad1 and zymogen granule protein 16 (Zg16) genes has been 
reported to be associated with the immunogenicity of iPS cells (Zhao et al., 2011). They 
were highly expressed in shrinking iPS teratomas upon syngeneic transplantation (Zhao 
et al., 2011), however this finding remains controversial. Araki et al. indicated that the 
expression of Hormad1 and Zg16 genes was not at an elevated level in regressing 
teratomas (Araki et al., 2013). Furthermore, Hormad1 and Zg16 expression was similar 
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among undifferentiated pluripotent stem cells or their tissue-specific differentiated three 
germ layer cells (endothelial cells, hepatocytes and neuronal cells, Guha et al., 2013). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.23. Immune-related gene expression in Ser-iPS cell teratomas. 
A: Expression of Hormad1 and Zg16 genes in Ser-iPS cell teratomas from B6 mice. Teratomas 
from MEF-iPS cells and ES cells were used as controls. Relative gene expression was 
normalized to β-actin. The average mRNA level in ES cell teratomas was arbitrarily set to 1. 
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B: Summary of Hormad1 and Zg16 gene expression in both larger and smaller teratomas from 
Ser-iPS cells. Teratomas from MEF-iPS cells and ES cells were controls as in (A). The average 
mRNA level in ES cell teratomas was arbitrarily set to 1. Ser-iPS cells: n=21; MEF-iPS cells: n=6; 
ES cells: n=5. Bars represent mean ± standard deviation. 
C-D: IL10 and ICAM1 gene expression in teratomas from Ser-iPS cells. Teratomas from MEF-iPS 
cells and ES cells were used as controls in (A). The average mRNA level in ES cell teratomas 
was arbitrarily set to 1. For IL10 gene expression, Ser-iPS cells: n=19; MEF-iPS cells: n=8; ES 
cells: n=10. For ICAM1 gene expression, Ser-iPS cells: n=13; MEF-iPS cells: n=8; ES cells: n=10. 
Average values of Ser-iPS cell 1, 2 and 3 and MEF-iPS cell 1 and 2 in (A), (B), (C) and (D) are as 
in Figure 4.11. All Ser-iPS cells and MEF-iPS cells are passage 9-15 (early-passage). * indicates 
P < 0.05. ** indicates P < 0.01. Bars represent mean ± standard deviation.  
 
Expression of molecules related to immunogenicity of pluripotent stem cells  
Expression of Hormad1 and zymogen granule protein 16 (Zg16) genes has been 
reported to be associated with the immunogenicity of iPS cells (Zhao et al., 2011). They  
were highly expressed in shrinking iPS teratomas upon syngeneic transplantation (Zhao 
et al., 2011), however this finding remains controversial. Araki et al. indicated that the 
expression of Hormad1 and Zg16 genes was not at an elevated level in regressing 
teratomas (Araki et al., 2013). Furthermore, Hormad1 and Zg16 expression was similar 
among undifferentiated pluripotent stem cells or their tissue-specific differentiated three 
germ layer cells (endothelial cells, hepatocytes and neuronal cells, Guha et al., 2013). 
 
To investigate the expression of Hormad1 and Zg16 genes in Ser-iPS cell teratomas, 
both larger and smaller teratomas from syngeneic B6 mice were examined by qRT-PCR. 
No significantly different expression of Hormad1 and Zg16 genes was observed between 
larger and smaller teratomas, and most of the teratomas showed low expression of these 
two genes (Figure 4.23A). Surprisingly, the expression of Zg16 gene was much higher in 
teratomas from Ser-iPS cells than that of MEF-iPS cells, which seems contradictory to 
the reduced immunogenicity of Ser-iPS cells. For the expression of Hormad1 gene, no 
significant difference was found between Ser-iPS cell and MEF-iPS cell teratomas, as 
well as ES cell teratomas. Furthermore, both Ser-iPS cell and MEF-iPS cell teratomas 
showed lower expression level of Hormad1 and Zg16 than ES cell teratomas (Figure 
4.23B). Thus, expression of Hormad1 and Zg16 genes is apparently unrelated to 
teratoma regression and iPS cell immunogenicity. 
 
Further investigation of other genes that might be related to Ser-iPS cell immunogenicity 
was performed by qRT-PCR. The expression of anti-inflammatory cytokine interleukin 10 
(IL10) and intercellular adhesion molecule 1 (ICAM1) genes in teratomas was analyzed. 
Unexpectedly, expression of IL10 gene was significantly lower in teratomas from Ser-iPS 
cells than in those of MEF-iPS cells (Figure 4.23C). Considering the higher frequency of 
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teratomas formed by Ser-iPS cells, IL10 expression appears to more strongly correlated 
to the immune rejection of iPS cells than their survival, which is consistent with a 
previous study (Robertson et al., 2007). ICAM1, which is upregulated by inflammatory 
cytokines, plays an important role for leukocyte travel and adhesion during immune 
response (Long 2011). Expression of ICAM1 gene in Ser-iPS cell teratomas was lower 
than in MEF-iPS cell and ES cell teratomas (Figure 4.23D). This finding indicates that 
ICAM1 gene expression might partially contribute to the different immune cell infiltration 
in teratomas from Ser-iPS cells and MEF-iPS cells. 
 
Expression of molecules involved in immune-privileged function of Sertoli cells 
Given the reduced immunogenicity of Ser-iPS cells, some of the immune-protective 
molecules, which contribute to the immune-privileged function of Sertoli cells, might be 
preserved in Ser-iPS cells. Therefore, the molecules related to the immune-privileged 
function of Sertoli cells were examined. EBs and teratomas from Ser-iPS cells were 
analyzed by qRT-PCR. Expression of arginase 1 and prostaglandin E2 (PGE2) genes 
are shown here. Arginase 1, expressed in Sertoli cells, hydrolyzes arginine into urea and 
ornithine (Guo et al., 2007). It is also expressed in human and mouse ES cells, inhibits T 
cell responses, which results in downregulation of TCR CD3-ζ chain and attenuated T 
cell activation. This was further confirmed by in vivo experiments that T cell infiltrating 
teratomas derived from mouse ES cells showed significantly lower CD3-ζ chain 
expression (Yachimovich-Cohen et al., 2010).  
 
Sertoli cells express arginase 1, which is involved in immune suppression, and thus the 
question is whether arginase 1 expression in Sertoli cells contributes to the reduced 
immunogenicity of Ser-iPS cells. Arginase 1 expression in both EBs (day 14 of 
differentiation) and teratomas of Ser-iPS cells was analyzed by qRT-PCR. Indeed, higher 
expression of arginase 1 in Sertoli cells than MEF was found. Furthermore, much higher 
expression of arginase 1 was observed in EBs of Ser-iPS cells than those of MEF-iPS 
cells. While no significant difference of arginase 1 expression was found in Ser-iPS cell 
and MEF-iPS cell teratomas (Figure 4.24A). Arginine depletion by arginase 1 causes a 
downregulation of CD3-ζ chain (Rodriguez et al., 2002; Baniyash 2004). Thus, the 
expression of CD3-ζ chain in Ser-iPS cell teratomas was analyzed. No significantly 
different expression of CD3-ζ chain was observed between teratomas from Ser-iPS cells 
and MEF-iPS cells, as well as teratomas from ES cells (Figure 4.24B). This is consistent 
with the expression of arginase 1 in teratomas. Another immunosuppressive factor, 
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PGE2, was higher expressed in Sertoli cells than MEF, as well as higher expressed in 
Ser-iPS cell teratomas than MEF-iPS cell teratomas (Figure 4.24C). 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  
Figure 4.24. Expression of molecules related to the immune-privileged function of Sertoli 
cells in EBs and teratomas from Ser-iPS cells. 
A: Arginase 1 expression in EBs (left panel) and teratomas (right panel) of Ser-iPS cells was 
examined by qRT-PCR. Corresponding MEF-iPS cells and ES cells were taken as controls. 
Sertoli cells and MEF were used as positive and negative control, respectively. mRNA level in 
MEF was arbitrarily set to 1. Replication for the expression of arginase 1 in teratomas: Ser-iPS 
cells: n=14; MEF-iPS cells: n=3; ES cells: n=3. * indicates P<0.05. Bars represent mean ± 
standard deviation. 
B: Expression of CD3-ζ chain in Ser-iPS cell teratomas by qRT-PCR. Teratomas from MEF-iPS 
cells and ES cells were taken as controls. Spleen was used as a positive control. The average 
mRNA level in ES cell teratomas was arbitrarily set to 1. Replication for the expression of CD3-ζ 
chain in teratomas: Ser-iPS cells: n=12; MEF-iPS cells: n=5; ES cells: n=5. Bars represent mean 
± standard deviation. ES ave: ES average. 
C: Expression of PGE2 in Ser-iPS cell teratomas. Corresponding MEF-iPS cells and ES cells 
were taken as controls. Sertoli cells and MEF were used as positive and negative control, 
respectively. mRNA level in MEF was arbitrarily set to 1. Replication for the expression of PGE2 
in teratomas: Ser-iPS cells: n=13; MEF-iPS cells: n=8; ES cells: n=10. Average values of Ser-iPS 
cell 1, 2 and 3 and MEF-iPS cell 1 and 2 in (A), (B) and (C) are as in Figure 4.11. All Ser-iPS cells 
and MEF-iPS cells are passage 9-15 (early-passage). ** indicates P<0.01. Bars represent mean ± 
standard deviation. 
 
By allogeneic transplantation of primary Sertoli cells, Doyle and colleagues suggested 
that the mechanisms responsible for Sertoli cell immune-privileged function are favoring 
a type 2 immune response, immature DC and Tregs (Doyle et al., 2012). To address if 
Ser-iPS cells retain these functions of Sertoli cells, the frequency of Tregs and gene 
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expression representing type 1 and type 2 immune responses were examined by qRT-
PCR. No significant difference of Foxp3 expression was observed between teratomas 
from Ser-iPS cells and MEF-iPS cells, as well as from ES cells (Figure 4.25A). IFNγ and 
IL-4 genes are representative markers for type 1 (destructive) and type 2 (protective) 
immune responses, respectively. The expression of IFNγ gene in Ser-iPS cell teratomas 
was lower compared to that of MEF-iPS cells, however this did not reach statistical 
significance. The expression of IL-4 gene was similar in teratomas of Ser-iPS cells and 
MEF-iPS cells, as well as teratomas of ES cells (Figure 4.25B). 
 
Taken together, the expression of MHC class I and MHC class II, costimulatory 
molecules (CD80 and CD86), Hormad1 and Zg16 genes do not seem to be responsible 
for the reduced immunogenicity of Ser-iPS cells. ICAM1, PGE2 and arginase 1 genes, 
which relate to the immune-privileged function of Sertoli cells, were found differently 
expressed in teratomas or EBs derived from Ser-iPS cells and MEF-iPS cells. Thus 
expression of ICAM1, PGE2 and arginase 1 genes might contribute to the reduced 
immunogenicity of Ser-iPS cells. However, Ser-iPS cells failed to retain Sertoli cell 
immune functions, which switch type 1 to type 2 immune response and favor Treg 
generation in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.25. Expression of Foxp3, IFNγ  and IL-4 genes in teratomas from Ser-iPS cells. 
A-B: Foxp3, IFNγ and IL-4 gene expression in Ser-iPS cell teratomas was examined by qRT-PCR. 
Teratomas from MEF-iPS cells and ES cells were used as controls. Spleen was taken as a 
positive control. Average mRNA level in ES cell teratomas was arbitrarily set to 1. Average values 
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of Ser-iPS cell 1, 2 and 3 and MEF-iPS cell 1 and 2 in (A) and (B) are as in Figure 4.11. All Ser-
iPS cells and MEF-iPS cells are passage 9-15 (early-passage). Bars represent mean ± standard 
deviation. 
4.6 Transdifferentiation MEF to hematopoietic cells 
With different culture conditions and appropriate transcriptional factors ectopic 
expression, somatic cells can be directly reprogrammed into another kind of adult stem 
cells or differentiated cells without establishing a pluripotent state (Szabo et al., 2010). 
Cell types with tissue-specific conditional mutants are very important for this process, 
since it is much easier for monitoring successful transdifferentiation.  
4.6.1 Generation of Vav-iCre/Rosa26R-fGFP mice 
For transdifferentiation of MEF into hematopoietic cells, Vav-iCre mouse line was 
selected, which expresses Cre recombinase in hematopoietic tissues under the control 
of Vav regulatory elements (de Boer et al., 2003; Kwon et al., 2008; a kind gift of Dimitris 
Kioussis, London, UK and Meinrad Busslinger, IMP, Vienna, Austria; Figure 4.26A, 
upper panel). Vav gene expresses in virtually all murine hematopoietic cell types and 
also hematopoietic stem cells (Adams et al., 1992; Katzav et al., 1989 and Bustelo et al., 
1993). Furthermore, the Vav promoter elements can efficiently and exclusively initiate  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.26. Schematic representation of Cre expression and Rosa26R-fGFP structure 
used to generate Vav-iCre/Rosa26R-fGFP mice. 
A: Cre expression under the control of Vav promoter (upper panel). Rosa26R-fGFP structure 
contains loxP sites and EGFP under the control of CAG promoter (lower panel). pA represents 
poly A sequence. CAG promoter: chicken beta-actin promoter with cytomegalovirus enhancer. 
B: Scheme for generation of Vav-iCre/Rosa26R-fGFP mice.  
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transgene expression in almost all nucleated hematopoietic cells independent of 
integration position (Ogilvy et al., 1999a and Ogilvy et al., 1999b). Another mouse line 
used is Rosa26R-fGFP mouse, which contains loxP sites flanking a STOP cassette in 
front of farnesylated eGFP (Rawlins et al., 2009; a kind gift of Emma L Rawlins, Gurdon 
Institute, Cambridge, UK). Membrane-targeted eGFP is expressed after Cre-mediated 
excision of the STOP cassette (Figure 4.26A, lower panel). To generate Vav-
iCre/Rosa26R-fGFP mice that express eGFP in hematopoietic cells under the control of 
Vav promoter, Vav-iCre mice were crossed with Rosa26R-fGFP mice (Figure 4.26B). 
Heterozygote mice (Vav-iCre/Rosa26R-fGFP+/-) were obtained. To test GFP expression 
in hematopoietic cells, blood and BM samples from these heterozygote mice were 
isolated and analyzed for GFP expression in different types of hematopoietic cells by 
flow cytometry or microscopy.  
 
In blood samples from heterozygote mice, about 95% CD45+ cells expressed GFP, while 
still 5% CD45+ cells were GFP-. For T cell (CD4 and CD8) and DC (CD11b), almost all 
the cells expressed GFP (100%); for B cell (CD19) and macrophage (F4/80), about 99% 
of these cells were GFP+, only 1% of the cells were GFP- (Figure 4.27A). The 
expression of GFP fluorescence in BM cells from heterozygote mice was detected with 
microscopy. Most of the BM cells expressed GFP fluorescence, in contrast to BM cells 
from wt mice, which were absolutely GFP- (Figure 4.27B). These data indicate that Vav 
promoter and Cre-mediated excision of the loxP sites are effective in hematopoietic cells 
from Vav-iCre/Rosa26R-fGFP+/- mice. Thus, Vav-iCre/Rosa26R-fGFP mice can be used 
as cell source for detection of successfully transdifferentiate somatic cells into 
hematopoietic cells. 
4.6.2 Vav-MEF preparation by MACS 
The purity of initiating cells is extremely important for successful transdifferentiation. 
Here, terminally differentiated MEF were used for transdifferentiation. MEF were isolated 
from day 13.5 pregnant Vav-iCre/Rosa26R-fGFP+/+ mice; in the following referred to as 
Vav-MEF. Vav-MEF were prepared as described before (Methods 3.2) and purified with 
MACS to avoid potential contamination of hematopoietic cells. MACS selected Vav-MEF 
were infected with retroviral vectors expressing Oct4 or Oct4 plus Bmi1 to generate 
hematopoietic cells. Cells were cultured under HSC condition in the presence of 
cytokines (SCF, hyper-IL-6, Flt3 ligand and human IGF1; hereafter referred to as 
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complete HSC medium), which is a commonly used medium for HSC in our lab. When 
non-adherent cells emerged, cells were collected and analyzed by flow cytometry (Figure 
4.28). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.27. GFP expression in hematopoietic cells from Vav-iCre/Rosa26R-fGFP+/- mice. 
A: Flow cytometry analysis of blood cells from heterozygote Vav-iCre/Rosa26R-fGFP mice.  
Blood cells from wt mice were used as control. Cells were stained with antibodies at 4°C for 30 
min. GFP expression in different types of hematopoietic cells was examined. Numbers depict the 
percentages of corresponding populations. WT: wild type; Heter: heterozygote. 
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B: Microscopy of BM cells from heterozygote Vav-iCre/Rosa26R-fGFP mice. Representative 
images of GFP expression in hematopoietic cells from wt mice (upper panel) and heterozygote 
mice (lower panel) are shown. Images were taken immediately after the isolation of BM cells. PH: 
phase contrast. Scale bar represents 800 µm.	  
Figure 4.28. Schematic representation of transdifferentiation Vav-MEF into hematopoietic 
cells. 
Step 1: Vav-MEF were isolated from day 13.5 pregnant homozygote Vav-iCre/Rosa26R-fGFP 
mice. After one passage, Vav-MEF were purified by negative selection with CD45 MicroBeads to 
remove hematopoietic cells. 
Step 2: MACS purified Vav-MEF were infected with retroviral vectors expressing transcriptional 
factor Oct4 or the combination of Oct4 and Bmi1. Infected cells were cultured in MEF medium. 
Five days after infection, MEF medium was refreshed with complete HSC medium and changed 
every two days until non-adherent cells emerged. 
Step 3: At day 29 after infection, non-adherent cells were collected and analyzed by flow 
cytometry. At day 36 after infection, remaining adherent cells were trypsinized into single cells 
and harvested for flow cytometry. 
 
Purity of Vav-MEF was determined by flow cytometry immediately after MACS selection. 
Unstained CD1 MEF were used as control. Actually, freshly isolated Vav-MEF were not 
absolutely homogeneous population. The purity of Vav-MEF increased from 97.5% 
(before MACS) to 99% (after MACS; Figure 4.29). This purification procedure is 
necessary for hereafter transdifferentiation to avoid the possible contamination of 
hematopoietic cells.  
 
 
 
 
 
 
 
 
 
Figure 4.29. Purity of Vav-MEF after MACS selection. 
Vav-MEF were purified by negative selection with CD45 MicroBeads. Unstained CD1 MEF were 
used as control. Purified Vav-MEF were analyzed by flow cytometry as CD45-GFP- cells. 
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Numbers depict the percentage of corresponding populations. Con: control. Before: purity of Vav-
MEF before MACS selection. After: purity of Vav-MEF after MACS selection. 
4.6.3 Transdifferentiation MACS selected Vav-MEF to hematopoietic cells 
To generate hematopoietic cells, MACS purified Vav-MEF were infected with retrovirus 
expressing Oct4 or Oct4 plus Bmi1 in the presence of PB (8 µg/ml). Infected Vav-MEF 
were cultured in complete HSC medium. At about day 23 after infection, non-adherent 
cells emerged from both Oct4 and Oct4 plus Bmi1 infected Vav-MEF (Figure 4.30).  
Figure 4.30. Emergence of non-adherent cells from retrovirus infected Vav-MEF. 
Non-adherent cells emerged at about day 23 after infection. Images were taken at day 25 after 
infection. Con: Vav-MEF cultured in complete HSC medium without retrovirus infection.  
 
The non-adherent cells emerging from Oct4 plus Bmi1 infected Vav-MEF were 3 days 
ahead in time compared to Oct4 infected Vav-MEF. The non-adherent cells emerged as 
clones and kept proliferating for several days. At about day 27 after infection, non-
adherent cells seemed to stop proliferating and the quantity of non-adherent cells 
decreased. Then at day 29 after infection, these non-adherent cells were collected by 
gently washing with PBS for several times and stained the cells with APC-Cy7-
conjugated CD45 and Pacific Blue-conjugated F4/80 antibodies. The remaining adherent 
cells were kept in culture with complete HSC medium. 
 
Compared to control MEF, there were obvious two populations of non-adherent cells 
from Oct4 and Oct4 plus Bmi1 infected Vav-MEF. The two populations were gated 
separately and analyzed for the expression of CD45, F4/80 (macrophage marker) and 
GFP. In population Ⅰ, most of the non-adherent cells were CD45+ cells (Oct4: 98.5% vs 
Oct4+Bmi1: 99.1%), while only part of the cells expressed GFP (Oct4: 36.7% vs 
Oct4+Bmi1: 19.6%). These data do not fit the tested blood samples from heterozygote 
mice, in which about 95% CD45+ cells were GFP+ (Figure 4.27A). This is probably 
because microscopy was used for selection of homozygote embryos for Vav-MEF 
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preparation. Due to autofluorescence by microscopy, it might be difficult to guarantee 
only homozygote embryos were selected and this might cause that only some 
CD45+cells were also GFP+. There was almost no expression of F4/80 gene in 
population Ⅰ (Figure 4.31).  
Figure 4.31. Generation of hematopoietic cells from Vav-MEF. 
Non-adherent cells were collected at day 29 after infection and stained with APC-conjugated-
CD45 and Pacific Blue-conjugated-F4/80 antibodies. Expression of CD45, F4/80 and GFP was 
determined by flow cytometry. Numbers depict the percentage of corresponding populations. Ⅰ, Ⅱ 
represent two different populations in non-adherent cells. Con: control. FSC: Forward Scatter. 
SSC: Side Scatter. 
 
In population Ⅱ, most of the cells expressed both CD45 (Oct4: 98% vs Oct4+Bmi1: 98%) 
and GFP (Oct4: 93.6% vs Oct4+Bmi1: 87%), only really small part of the cells were 
CD45-GFP- (about 2%). There was still almost no expression of F4/80 gene in Oct4 
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infected Vav-MEF (1.5%). However, for Oct4 plus Bmi1 infected Vav-MEF, much more 
macrophages were found (31%; Figure 4.31). 
 
However, after several days culturing of remaining adherent cells with complete HSC 
medium, no non-adherent cells emerged anymore. Then after 36 days of infection, these 
adherent cells were trypsinized, stained with CD45 and F4/80 antibodies and analyzed 
by flow cytometry. These remaining adherent cells, even cultured in complete HSC 
medium, failed to be converted into hematopoietic cells. They did not express CD45 and 
F4/80, and also no GFP+ cells emerged (Figure 4.32). Thus, MACS purified Vav-MEF 
can be transdifferentiated into hematopoietic cells by infection with retrovirus expressing 
Oct4 alone or Oct4 plus Bmi1. 
 
 
 	  	  	  	  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.32. Expression of hematopoietic cell markers in remaining adherent cells. 
Remaining adherent cells were trypsinized to single cells 36 days after infection. These cells were 
stained with APC-conjugated-CD45 and Pacific Blue-conjugated-F4/80 and analyzed by flow 
cytometry with the expression of CD45, F4/80 and GFP. Numbers depict the percentage of 
corresponding populations. 
4.6.4 Vav-MEF preparation by FACS sorting 
For MACS purified Vav-MEF, there were still about 1% of CD45+ and/or GFP+ cells left 
before infection with retrovirus expressing Oct4 and Oct4 plus Bmi1. This small part of 
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potential hematopoietic cells might serve as a source of hematopoietic cells and keep 
proliferating during in vitro culture in complete HSC medium. To further purify Vav-MEF 
and avoid possible contamination from remaining hematopoietic cells, CD45-GFP- Vav-
MEF were selected by FACS. To ensure Vav-MEF were obtained from Vav-
iCre/Rosa26R-fGFP+/+ embryos, Vav-MEF were isolated separately from each embryos 
and homozygote Vav-MEF were selected according to genotyping results. Vav-MEF 
were isolated from day 13.5 pregnant homozygote mice as aforementioned (Methods 
3.2) and sorted for CD45-GFP- cells. Desired Vav-MEF (CD45-GFP-) were gated strictly 
to avoid potential contamination of hematopoietic cells. Primary Vav-MEF were 
heterogeneous and did include CD45+ and/or GFP+ cells (about 4.4%; Figure 4.33A). 
After FACS sorting, Vav-MEF were kept in culture to let them recover from the sorting 
stress. Purity of Vav-MEF was immediately tested by flow cytometry. Before FACS 
sorting, the purity of Vav-MEF (CD45-GFP-) was about 98%, and the purity of Vav-MEF 
increased to 99.8% after FACS sorting (Figure 4.33B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.33. Purity of FACS purified Vav-MEF. 
A: FACS selection of purified Vav-MEF as CD45-GFP- cells. Numbers depict the percentage of 
corresponding populations. FSC: Forward Scatter. SSC: Side Scatter. 
B: Purity of Vav-MEF was analyzed by flow cytometry. Purified Vav-MEF were referred to as 
CD45-GFP- cells. Unstained CD1 MEF were used as control. Con: Control. Before: Purity of Vav-
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MEF before sorting. After: Purity of Vav-MEF after sorting. Numbers depict the percentage of 
corresponding populations. 
 
FACS sorting purified Vav-MEF were infected with retroviral vectors expressing Oct4 and 
Oct4 plus Bmi1. Infected cells were cultured in the same condition as MACS purified 
Vav-MEF (see 4.6.3). However, after 30 days of culture with complete HSC medium, 
there were still no non-adherent cells emerged as MACS purified Vav-MEF and FACS 
sorting purified Vav-MEF became apoptotic. Therefore, FACS sorting purified Vav-MEF 
failed to be transdifferentiated into hematopoietic cells after infection with retrovirus 
expressing Oct4 and Oct4 plus Bmi1 in complete HSC medium. 
 
In summary, MACS purified Vav-MEF were successfully transdifferentiated into 
hematopoietic cells by retrovirus expressing Oct4 and Oct4 plus Bmi1. However, FACS 
sorting purified Vav-MEF failed to be transdifferentiated into hematopoietic cells in the 
same conditions. It is possible that transdifferentiated hematopoietic cells from MACS 
purified Vav-MEF might come from the proliferation of residual hematopoietic cells (1% 
CD45+ and/or GFP+ cells). While residual hematopoietic cells from FACS sorted Vav-
MEF were only 0.2% (CD45+ and/or GFP+ cells), which might explain the different 
results from the same infection. Therefore, Oct4 or Oct4 plus Bmi1 over-expression in 
Vav-MEF dose not seem to possess the potential to transdifferentiate Vav-MEF into 
hematopoietic cells. 
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5 DISCUSSION 
iPS technology represents a new reprogramming method that directly induce somatic 
cells into a pluripotent state by resetting the somatic cell epigenetic state. During this 
reprogramming process, somatic gene expression is switched off and at the same time, 
the pluripotency program is activated, which further progresses into a stable pluripotent 
state. However, somatic gene expression is not completely inactivated in the early stage 
of pluripotency. Incomplete inactivation of somatic gene expression results in somatic 
memory, which will in turn affect the characteristics and functions of resulting iPS cells. 
In view of somatic memory, choosing the appropriate starting cells for cellular 
reprogramming is critical for further applications of iPS cells. 
 
The first part of this thesis focuses on immunogenicity of iPS cells derived from immune-
privileged Sertoli cells. This study demonstrates that Ser-iPS cells exhibit low 
immunogenicity both in vivo and in vitro. Ser-iPS cells formed teratomas at a higher 
frequency compared to MEF-iPS cells upon syngeneic transplantation into B6 mice. 
Moreover, Ser-iPS cell teratomas exhibited less T cell, B cell and DC infiltration, and 
tissue damage and necrosis compared to those of MEF-iPS cells. Furthermore, EBs 
formed by Ser-iPS cells showed lower T cell stimulation potential in in vitro co-culture 
experiment. Thus, Ser-iPS cells show reduced immunogenicity and this may be due to 
some residual somatic memory, originating from immune-privileged Sertoli cells used for 
reprogramming. 
 
Transdifferentiation is another promising method to reprogram one cell type directly into 
another. It avoids potential tumorigenesis risk of iPS cells, because transdifferentiation 
bypasses the pluripotent stage during reprogramming. The second part of this thesis 
focuses on transdifferentiation Vav-MEF into hematopoietic cells. In this study, Vav-MEF 
were used that allow monitoring of hematopoietic cells, which emerge after 
transdifferentiation. Both MACS and FACS purified Vav-MEF were used for 
transdifferentiation into hematopoietic cells. MACS selected Vav-MEF yielded 
hematopoietic cells by infection with retrovirus expressing Oct4 and Oct4 plus Bmi1, 
which might be due to some residual hematopoietic cells in the starting cell population. 
Hematopoietic cells failed to emerge after transfection of FACS purified Vav-MEF with 
the same transcription factors. Thus, Oct4 and Oct4 plus Bmi1 transcriptional factors do 
not seem to have the potential to transdifferentiate Vav-MEF into hematopoietic cells. 
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5.1 Reduced immunogenicity of Ser-iPS cells 
Autologous iPS cells are an attractive cell source for personalized regenerative medicine, 
yet their immunogenicity is still a great challenge for their future applications. Previous 
studies showed the immunogenicity of iPS cells by transplantation them into syngeneic 
hosts (Zhao et al., 2011). However, the immunogenicity of iPS cells and iPS cell-derived 
cells has remained highly controversial (Araki et al., 2013; Guha et al., 2013; de Almeida 
et al., 2014). As cells of origin impact on the properties of iPS cells, using less 
immunogenic cells for iPS cell generation might translate into a low immunogenicity of 
obtained iPS cells (Boyd et al., 2012; Liu et al., 2013). Here immune-privileged Sertoli 
cells were used to generate iPS cells and Ser-iPS cells did possess reduced 
immunogenicity compared to the corresponding MEF-iPS cells. 
5.1.1 Teratoma formation of Ser-iPS cells 
Many factors might influence the immunogenicity of in vitro differentiated cells in 
transplantation, such as in vitro culture conditions (Scheiner et al., 2014), cell types for 
transplantation (Cao et al., 2014) and transplantation sites (Scheiner et al., 2014). In vivo 
immunogenicity of Ser-iPS cells was examined by teratoma assay. Teratoma assay is 
frequently used to evaluate the immunogenicity of pluripotent stem cells and their 
derivatives in vivo (Koch et al., 2008; Zhao et al., 2011). Teratoma harbors a variety of 
differentiated cell types similar to the normal derivatives of all three germ layers (Tapper 
and Lack 1983). Thus, teratoma provides an useful model for simultaneously assessing 
the immunogenicity of various differentiated cell types from iPS cells (Boyd et al., 2012; 
Zhao et al., 2011). In this assay, tumor formation indicates that the recipient’s immune 
system fails to reject tumor-forming cells (Dressel 2011).  
 
Here, we found that Ser-iPS cells have a much stronger capacity to regulate the 
recipient’s immune response compare to MEF-iPS cells. This immune regulatory ability 
allows Ser-iPS cells to form teratomas at high frequency. Thus, Ser-iPS cells possess 
low immunogenicity in teratoma formation assays in in vivo. Matrigel, which contains 
numerous active growth factors, can increase teratoma formation efficiency of both 
mouse and human ES cells (Lawrenz et al., 2004; Prokhorova et al., 2009). Therefore, 
matrigel and DMEM mixture (1:4) was used to suspend iPS cells and ES cells for 
teratoma assay. 
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5.1.2 Immune responses induced by Ser-iPS cells in vivo 
Ser-iPS cells formed teratomas at a high efficiency upon syngeneic transplantation, 
which is first evidence of their reduced immunogenicity. Furthermore, Ser-iPS cells 
appear to prevent efficient infiltration of host derived immune cells into teratomas, such 
as T cell, B cell and DC. Low T cell infiltration in Ser-iPS cell teratomas was confirmed by 
both immunohistochemical staining and qRT-PCR. Such low T cell infiltration is 
consistent with less tissue damage and necrosis in Ser-iPS cell teratomas, since tissue 
destruction goes along with infiltration of activated T cells (Boyd et al., 2012; Zhao et al., 
2011). DC, as robust antigen-presenting cells, presents exogenous antigens to recipient 
T cells either by direct or indirect pathway (Kadereit and Trounson 2011). Such antigen-
presenting pathways correspond to respective T cell rejection patterns (direct and 
indirect T cell rejection, Kadereit and Trounson 2011; Liu et al., 2013). iPS cells did not 
directly differentiate into DC (Robertson et al., 2007), and thus antigen recognition in 
teratoma assay is most likely through indirect pathways, where donor antigens are 
recognized by recipient DC, and further presented to recipient T cells, which results in 
immune activation (Kadereit and Trounson 2011).  
5.1.3 Immune responses induced by Ser-iPS cells in vitro 
In vivo immune responses are complex processes, which involve multiple interactions 
between different immune cell types, including T cell, B cell and DC. The important role 
of CD4 T cells during immune responses has been reported (Drukker et al., 2006; 
Swijnenburg et al., 2008). In vitro co-culture is commonly used to investigate possible 
immune responses induced by stimulator cells. Thus, further insights of Ser-iPS cell 
immunogenicity were obtained by in vitro co-culture of CD4 T cells with undifferentiated 
and EBs of Ser-iPS cells. EB assay represents the in vitro equivalent of teratoma 
formation in vivo. EBs of Ser-iPS cells exhibited less potential in stimulating T cell 
proliferation compared to that of MEF-iPS cells. However, both Ser-iPS cells and MEF-
iPS cells in their undifferentiated state showed T cell response similar to ES cells. Thus, 
the immunogenicity of iPS cells was found to be related to the somatic cells used for 
reprogramming and to the differentiated state. 
 
Previous studies indicated that the immune-privileged function of sertoli cells includes 
the generation of Tregs (Dal Secco et al., 2008; Doyle et al., 2012). Therefore, whether 
Ser-iPS cell immunogenicity was related to the generation of Tregs was investigated 
here. Ser-iPS cells showed a Treg profile similar to MEF-iPS cells and ES cells in co-
culture experiments. Results obtained here also confirmed Treg generation function of 
Sertoli cells (Dal Secco et al., 2008). Since there is a difference in in vivo and in vitro 
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environments, it is also worth investigating the frequency of Tregs in teratomas. Foxp3 
expression in teratomas from Ser-iPS cells and MEF-iPS cells was found to be 
comparable. Thus, the reduced immunogenicity of Ser-iPS cells in vitro and in vivo 
appears to be unrelated to the Treg profile. 
5.1.4 Possible molecules involve in immunogenicity of pluripotent stem cells 
Considering the immunogenicity of iPS cells, syngeneic transplantation was used and 
several genes were identified during immune rejection (Zhao et al., 2011). Hormad1 and 
Zg16 genes, which were expressed in regressing iPS cell teratomas but not in ES cell 
teratomas, were reported to contribute to iPS cell immunogenicity (Zhao et al., 2011). 
However, this observation is still highly controversial and was not confirmed in follow up 
studies (Araki et al., 2013; Guha et al., 2013). This observation is also in contrast to the 
result reported here. A correlation between Hormad1 and Zg16 expression and iPS cell 
immunogenicity was not observed here. Hormad1, also called cancer/testis 46, involves 
in chromatin binding and highly expresses in testis. It has been identified as a tumor 
antigen (Chen et al., 2005). Zg16 is highly expressed in pancreas and down-regulated 
upon injury (Neuschwander-Tetri et al., 2004). In line with Arakia et al. and Guha et al. 
results, no obviously different expression of Hormad1 gene was observed between 
teratomas from Ser-iPS cells and MEF-iPS cells. Unexpectedly, much higher Zg16 
expression in Ser-iPS cell teratomas was found, which correlate inversely with the less 
immunogenicity of Ser-iPS cells, according to the results from Zhao et al.. Due to the 
elusive roles of Zg16 during teratoma formation, the exact roles of Zg16 during this 
immune response can not be explained at present. Thus, the level of Hormad1 and Zg16 
expression appears not to be related to the regression of teratomas and seems not to be 
important for the immunogenicity of iPS cells.  
 
Previous studies showed that ES cells possessed low immunogenicity compare to other 
somatic cells. Low expression of MHC class I, MHC class II and costimulatory molecules 
(CD80 and CD86) on ES cells partly contribute to their low immunogenicity and result in 
immune tolerance (Magliocca et al., 2006). Here the expression of MHC class I, MHC 
class II and costimulatory molecules (CD80 and CD86) was similar between Ser-iPS 
cells and MEF-iPS cells both in undifferentiated cells or day 14 differentiated EBs, as 
well as in corresponding ES cells. Therefore, the expression of MHC class I, MHC class 
II and costimulatory molecules seems to be unrelated to the reduced immunogenicity of 
Ser-iPS cells. 
 
DISCUSSION	  
	  	   85	  
Further to the aforementioned genes Hormad1 and Zg16, other genes might be implicate 
in the immune reponses and were investigated. The anti-inflammatory cytokines IL-10 
and cell membrane protein ICAM1 were expressed at lower levels in teratomas from Ser-
iPS cells. IL-10 is an important immune-modulatory molecule and can suppress the 
production of pro-inflammatory cytokines, costimulatory molecules and antigen 
presenting. The primary function of IL-10 appears to limit and terminate inflammatory 
responses (Moore et al., 2001). Thus, IL-10 seems to serve as an immune suppressive 
cytokine. Unexpectedly, IL-10 gene was expressed at lower levels in Ser-iPS cell 
teratomas as compared to MEF-iPS cells, which correlates inversely to reduced 
immunogenicity of Ser-iPS cells. However, the expression pattern of IL-10 gene is 
consistent with a previous study (Robertson et al., 2007), where IL-10 seems more 
related to tissue destruction. On the other hand, IL-10 is a responsive cytokine, and 
responses to pro-inflammatory stimuli (Li et al., 2012). Thus, it is possible that due to the 
higher immune responses during MEF-iPS cell transplantation, IL-10 might accelerate its 
production to blunt pro-inflammatory stimuli.  
 
ICAM1 is responsible for regulating migration and adherence of lymphocytes towards 
inflammatory sites. Increased expression of ICAM1 has been reported to associate with 
the activation of lymphocytes and maturation of macrophage-like cells (Dustin et al., 
1986). Thus, the significantly higher expression of ICAM1 in MEF-iPS cell teratomas 
indicates a more severe immune responses upon syngeneic transplantation compared to 
Ser-iPS cells. Further to IL-10 and ICAM1 genes, other immune-related genes might be 
involved in this immune response, which warrants further investigation. 
5.1.5 Possible somatic memory retained in Ser-iPS cells 
The existence of somatic memory in iPS cells has been reported previously (Marchetto 
et al., 2009; Ghosh et al., 2010). Somatic memory refers to some remnants of the 
epigenetic profile from the cell type used for reprogramming (Kim et al., 2010; Ohi et al., 
2011; Polo et al., 2010). This somatic memory influences the characteristics of iPS cells, 
such as iPS cells preferentially differentiate into cell lineage related to the cells used for 
reprogramming over unrelated lineages (Polo et al., 2010; Bar-Nur et al., 2011; Pfaff et 
al., 2012). However, the preferential re-differentiation of Ser-iPS cells into Sertoli cells 
was not observed here, based on the expresson of ABP, AMH and Sox9 in both Ser-iPS 
cell EBs and teratomas. Sox9 is continuously expressed in Sertoli cells (including pre-
Sertoli cells), which is upregulated by Sry activity, and in turn upregulates other genes 
related to proper differentiation of Sertoli cells (Kashimada and Koopman 2010). AMH is 
a member of the transforming growth factor-β family and a target of Sox9. AMH is 
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expressed in early Sertoli cells and in charge of regression of Müllerian duct (Arango et 
al., 1999). ABP is produced by Sertoli cells and is a biological marker of Sertoli cell 
function (Hagenas et al., 1975). Thus, Ser-iPS cells do not have the propensity to 
differentiate into the cell lineage of their origin.  
 
Immune protective molecules produced by Sertoli cells are the mainly contribution for the 
immune-privileged function of Sertoli cells (Doyle et al., 2012). These immune protective 
factors probably still preserved in Ser-iPS cells as somatic memory (Bar-Nur et al., 2011; 
Kim et al., 2010; Ohi et al., 2011; Polo et al., 2010). Arginase 1, which has an effect on 
urea cycle, hydrolyzes L-arginine into L-ornithine and urea (Guo et al., 2007). Arginase 
has been reported to be higly expressed in Sertoli cells (Guo et al., 2007). Indeed, higher 
arginase 1 expression was observed in Sertoli cells in my study. Interestingly, much 
higher arginase 1 expression in EBs of Ser-iPS cell was found compared to that of MEF-
iPS cells, but not in teratomas of Ser-iPS cells and MEF-iPS cells. Consistently, the 
expression of CD3-ζ chain, the only known gene regulated by arginase 1, was no 
difference in iPS cell and ES cell teratomas. The differential expression pattern of 
arginase 1 between iPS cell EBs and teratomas might be due to the complex cell types 
in teratomas. Such teratomas contained infiltrated host macrophages that also express 
arginase (Chen and Broome 1980). Thus, it is of interest to examine the expression of 
CD3-ζ chain in T cells after co-culture with EBs of Ser-iPS cell, due to the higher 
expression of arginase 1 in Ser-iPS cell EBs.  
 
PGE2, a pro-inflammatory factor with immune-suppressive activity, has been reported to 
suppress both innate and antigen-specific immune responses (Harris et al., 2002). PGE2 
expression inhibited T cell proliferation, enhanced T cell apoptosis and improved Th 2 
(protective) response while controlling the activation of CTL and NK cell mediated Th 1 
(destructive) immunity (Kalinski 2012). Thus, high expression of PGE2 in Ser-iPS cell 
teratomas, which might originate from Sertoli cells, could possibly contribute to the 
reduced immunogenicity of Ser-iPS cells.  
 
Sertoli cells provide an immune-privileged environment for developing germ cells partialy 
due to their ability to convert Th 1 (destructive) immune response to Th 2 immune 
response (Doyle et al., 2012), which more relates to immune modulation and tolerogenic 
(Meinhardt and Hedger 2011). However, the expression of IFNγ and IL-4, two genes 
representative for Th 1 and Th 2 immune response respectively, was similar in teratomas 
from Ser-iPS cells and MEF-iPS cells. Thus, the reduced immunogenicity of Ser-iPS 
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cells in vivo appears to be unrelated to Sertoli cell immune function that favors Th 2 
immune response. 
 
The mechanisms involve in Sertoli cell immune function are complicated and comprise 
further factors, such as multiple cytokines, chemokines, anti-inflammatory modulators, 
complement activation inhibitors and adhesion molecules (Doyle et al., 2012). Sertoli 
cells’ complex immune mechanism coupled with the potentionally preserved somatic 
memory in Ser-iPS cells make the mechanisms of Ser-iPS cell reduced immunogenicity 
even more complicated. The reduced immunogenicity of Ser-iPS cells is probably due to 
the interaction of multiple factors. Further investigation is warranted to elucidate the 
mechanisms involved in Sertoli cell immune function and how they contribute to the 
reduced immunogenicity of Ser-iPS cells. 
 
The reduced immunogenicity of Ser-iPS cells was observed in early-passage (p9-15) iPS 
cells. However, late-passage (p35-38) Ser-iPS cells exhibit an immunogenicity similar to 
the respective MEF-iPS cells in teratoma assay in syngeneic hosts. The low 
immunogenicity in early-passage Ser-iPS cells and its loss in late-passage Ser-iPS cells 
appears to be consistent with the presence of somatic memory in iPS cells. Somatic 
memory impacts on iPS cell properties at early stages (Kim et al., 2010; Ohi et al., 2011; 
Polo et al., 2010) and is erased upon continuous in vitro culture (Chin et al., 2009; Polo 
et al., 2010), similar to Ser-iPS cell immunogenicity reported here. However, the 
molecular events occurring during extended periods of culture have remained elusive: 
whether pluripotent cells get selected and occur in a high frequency or whether the 
exogenous reprogramming factors get silenced and/or the epigenetic reprogramming 
continues (Papp and Plath 2011). The exact underlying mechanisms for the loss of Ser-
iPS cell reduced immunogenicity during extended passaging have to await further 
studies.  
 
In summary, the immunogenicity of iPS cells derived from two different somatic cell types, 
immune-privileged Sertoli cells and MEF, was compared. Both Ser-iPS cells and MEF-
iPS cells, and their derivatives showed immunogenicity. Additionally, Ser-iPS cells 
exhibited reduced immunogenicity compared to MEF-iPS cells, which however got lost 
upon continuous in vitro culture. These findings indicate that somatic cell types have an 
impact on the immunogenicity of respective iPS cells. Our results reinforce the concept 
of using immune-privileged somatic cells for iPS cell generation and derivation of 
differentiated progeny for transplantation. 
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5.2 Transdifferentiation Vav-MEF to hematopoietic cells 
Transdifferentiation, an approach by which differentiated cell can be directly converted 
into other cell types, opens the perspective for to novel therapeutic strategies. With the 
increasing understanding of developmental biology, direct transdifferentiation by 
overexpression of critical transcriptional factors in vitro or by engineered cell 
transplantation in vivo has already been achieved (Islas et al., 2012; Yang et al., 2013; 
Rouaux and Arlotta 2013; Torper et al., 2013). Hematopoietic cells, which are normally 
difficult to differentiate from pluripotent stem cells in vitro, have also been obtained by 
infecting fibroblasts with different transcriptional factors (Szabo et al., 2010; Pereira et al., 
2013). Several important molecules are involved in hematopoiesis. Bmi1, which belongs 
to polycomb repression complex 1, plays a vital role in HSC self-renewal and 
hematopoietic cell differentiation from ES cells in vitro (Iwama et al., 2004; Rizo et al., 
2008; Ding et al., 2012). 
 
Unexpectedly, only MACS purified Vav-MEF (CD45-GFP-, purity: 99.1%) were 
transdifferentiated into hematopoietic cells, while FACS sorting selected Vav-MEF 
(CD45-GFP-, purity: 99.8%) failed to be transdifferentiated. Considering the entirely 
different results from the same transfection method, starting cells might be one of the 
reasons for this result. First, the purity of Vav-MEF selected by MACS and FACS sorting 
was different. The purity of Vav-MEF (CD45-GFP-) after MACS selection was 99.1%, 
which means an about 1% possible contamination with hematopoietic cells (CD45+ 
and/or GFP+); for Vav-MEF after FACS sorting, the possible residual hematopoietic cells 
were only about 0.2%. Thus, the hematopoietic cells obtained from MACS selected Vav-
MEF are probably the result of proliferation of residual hematopoietic cells in the starting 
cell population. Second, the purification methods are different. Vav-MEF with high purity 
were obtained by FACS sorting, however FACS sorting exerts more stress on cells 
compared to MACS, such as lower growth rate and higher mortality of cells after FACS 
sorting. This might also lead to the failure of transdifferentiation FACS sorting purified 
Vav-MEF into hematopoietic cells.  
 
In summary, successful transdifferentiation Vav-MEF into hematopoietic cells was not 
observed here as reported (Szabo et al., 2010). There are differences in preparation 
methods and purity of the starting cells, and also in the species used. Szabo and 
colleagues used human fibroblasts, while Vav-MEF were chosen as starting cells here. It 
is very well possible that the functions of same genes potentially vary between different 
species (human versus mouse). 
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5.3 Future perspectives 
With the development of iPS technique, significant discoveries have been achieved in 
this field. iPS cells, which resemble ES cells, provide an attractive and renewable cell 
source for degenerative disease treatment. However, many questions about iPS cells 
still remain and should be addressed before their clinical application. For example, what 
are the exact mechanisms for iPS generation; which transfection method is appropriate 
to generate reliable iPS cells, such as viral vectors, RNA and protein; how to enhance 
the efficiency and purity for generating differentiated cells from iPS cells. Although many 
questions should to be addressed, iPS cells, which are a potential replacement of ES 
cells, remain a promising tool for future application. Recently, iPS cells could be obtained 
by reprogramming in vivo and resulting iPS cells showed totipotency characteristics 
(Abad et al., 2013). Thus, in vivo production of iPS cells might represent a new method 
to generate iPS cell-derived cells for replacement therapy. 
 
iPS cells were generated from various somatic cell types, which in turn influence the 
properties of respective iPS cells through epigenetic mechanisms (Polo et al., 2010). 
Somatic memory in iPS cells leads to (i) DNA methylation according to parental somatic 
cells, (ii) preferential re-differentiation into cell lineages used for reprogramming and (iii) 
loss of somatic memory upon extended periods of in vitro culture (Bar-Nur et al., 2011; 
Kim et al., 2010; Ohi et al., 2011; Polo et al., 2010). As the origin of cells impact on the 
resulting iPS cells, choosing appropriate starting cells plays a critical role for subsequent 
application of iPS cells. As reported, neural progenitors from less immunogenic umbilical 
cord mesenchymal cell derived iPS cells exhibited lower immunogenicity compared to 
those from skin fibroblasts derived iPS cells (Liu et al., 2013). Reduced immunogenicity 
of iPS cells derived from immune-privileged Sertoli cells has been observed here. Thus, 
for generating desired differentiated cells from iPS cells for transplantation, somatic cells 
derived from immune-privileged sites, such as Sertoli cells, or somatic cells with low 
immunogenicity, such as cord blood, provide better cell sources. Furthermore, it is of 
interest to investigate the immunogenicity of specific differentiated cells from immune-
privileged cell derived iPS cells (like Ser-iPS cells). Thus, the low immunogenicity of iPS 
cell derived cells exploiting somatic memory holds new promise for regenerative 
medicine. 
 
Moreover, most of the studies focus on mouse iPS cells, the immunological activities of 
human iPS cells have not been systematically tested. Considering the time and cost that 
required for iPS cells generation from individual patient, several groups are trying to 
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establish iPS cell line banks that stock clinical-grade and human leukocyte antigen (HLA) 
matching iPS cell lines (Taylor et al., 2012; Kaneko and Yamanaka 2013). These HLA 
matched iPS cells will be used for future treatment of diseases. However, to what extent 
HLA matched iPS cells will avoid immune rejection and to what extent other factors (like 
culture conditions or miHA) will influence the immunogenicity of iPS cells remain elusive. 
So, it will be extremely important to select less immunogenic iPS clones or their 
differentiated derivaties as universal donors and monitor the immune responses after 
transplantation. 
 
Transdifferentiation provides a rapid way to generate novel cell types and functional 
tissues. It enables the generation of specific cell types and avoids potential 
tumorigenesis of iPS technology. Several groups focus on transdifferentiation into neural 
cells, including neural stem cells or differentiated neural cells, with different combination 
of transcriptional factors (Ambasudhan et al., 2011; Han et al., 2012; Pfisterer et al., 
2011; Thier et al., 2012; Vierbuchen et al., 2010). However, transdifferentiation into 
specific cell types, like hematopoietic cells, remains a big challenge.  
 
Given the advantages of transdifferentiation technology, many questions still need to be 
addressed. For example, first, whether transdifferentiated cells, similar to iPS cells, 
inherit somatic memory from their original cells needs to be investigated. Second, more 
work should be done with human cells, as successful transdifferentiation in mouse cells 
might be not work equally for human cells. Third, transfection methods play also an 
important role for subsequent application of the cells obtained, as observed in iPS cells. 
The last but not the least is that of immunogenicity of obtained transdifferentiated cells. 
Analogous to immunogenicity of syngeneic iPS cells, the question is on the 
immunogenicity of syngeneic transplanted transdifferentiated cells, which warrants 
further investigations. 
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7 APPENDIX 
7.1 Conditions for genotyping of Vav-iCre/Rosa26R-fGFP mice 
Conditions for genotyping of Vav-iCre mice 
Cre for: 5’-GCCTGCCCTCCCTGTGGATGCCACCT-3’ 
Cre rev: 5’-GTGGCAGAAGGGGCAGCCACACCATT-3’ 
 
PCR reaction mix 
 
10x Taq Pol buffer (NH4)2SO4 with MgCl2 5 µl 
dNTP (10 mM each) 1 µl 
Recombinant Taq DNA Polymerase 2 µl 
for primer 1 µl 
rev primer 1 µl 
DNA sample 2 µl 
Total volume 50 µl 
 
Reaction scheme 
 
Initiation 95°C 4 min  
Denaturation 95°C 30 sec  
36× Annealing 65°C 45 sec 
Extension 72°C 30 sec 
Final extension 72°C 10 min  
Termination 10°C ∞  
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Conditions for genotyping of Rosa26R-fGFP mice 
 
Rosa26 for: CACTTGCTCTCCCAAAGTCG 
Rosa26 rev: TAGTCTAACTCGCGACACTG 
CAG: GTTATGTAACGCGGAACTCC 
 
PCR reaction mix 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reaction scheme 
 
 
 
 
 
 
 
 
  
10x Taq Pol buffer (NH4)2SO4 2 µl 
25 mM MgCl2 2 µl 
dNTP (10 mM each) 0.4 µl 
Recombinant Taq DNA Polymerase 0.2 µl 
Rosa for primer 1.28 µl 
Rosa rev primer 0.64 µl 
CAG primer 0.64 µl 
DNA sample 1 µl 
H2O 11.84 µl 
Total volume 20 µl 
Initiation 96°C 3 min  
Denaturation 96°C 30 sec  
30× Annealing 60°C 30 sec 
Extension 72°C 1 min 
Final extension 72°C 10 min  
Termination 4°C ∞  
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